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REGULATION OF PI3K/AKT SIGNALLING PATHWAY IN PEDIATRIC ACUTE 
MYELOID LEUKEMIA (AML): A NOVEL TUMOUR-SUPPRESSOR PHLPP 
SUMMARY 
The constitutive activation of PI3K/Akt signaling pathway has been implicated in 
both pathogenesis and progression of Acute Myeloid Leukemia (AML). Upregulated 
PI3K/Akt pathway has been found to be associated with shorter overall survival in 
AML cases, which makes this pathway an important target for development of novel 
therapeutic strategies against AML. Two key proteins control the termination of Akt 
signaling: PTEN, a lipid phosphatase, that prevents activation by removing the 
second messenger that activates Akt, and PH domain and leucine rich repeat 
protein phosphatase, PHLPP, which inactivates Akt by direct dephosphorylation of 
the hydrophobic motif Ser473. In a number of studies, it was demonstrated that 
certain tumors were insensitive to inhibitors of PI3 kinase and to the overexpression 
of PTEN. Besides, it has been previously shown that PHLPP levels are markedly 
reduced in a number of colon cancer and glioblastoma cell lines as well as in 
chronic lymphocytic leukemia patients with deletion 13q14 and colon tumours. 
Considering these findings, the important role of PHLPP in Akt pathway regulation 
as a negative regulator and tumour suppressor emerges while making PHLPP an 
attractive target for development of innovative anti-cancer strategies. Human 
PHLPP contains four major functional domains; an amino-terminal PH domain, a 
leucine-rich repeat region (LRR), a PP2C-like catalytic core and a PDZ binding 
motif. So far, there are no described mutations in PHLPP gene. In this study, the 
architecture of PHLPP gene variations and the expression of four major functional 
domains of PHLPP gene together with PI3K/Akt pathway genes; Akt-1, PTEN and 
caspase-3 were examined. Mutation secreenings of 11 exons covering the four 
domains of PHLPP gene were performed in pediatric AML patients by DHPLC 
analysis. Mutation detection was accomplished by direct sequencing. The following 
sequence variations were found: exon2; 59insA(5.2%), 60T>G(2.8%), 
77C>A(2.8%), 109A>T, exon3; 289C>A(7.8%), 352C>A(7.8%), 343insA(2.8%), 
exon5; 599insA (47%), exon14; 1980T>C(5.2%), 1992T>C(5.2%), exon17; 
3280C>A(13.1%), 3302insA(13,1%), 3303T>C(13.1%), 3407insA(5.2%) and 
3611insC (7.8%). The expression studies were also performed in pediatric AML 
patients and in CD33+ healthy bone marrow cells by qRT-PCR. The results 
revealed that Akt was up-regulated in pediatric AML patients (OR=4.4 95%CI=0.04-
2.9, p=0.06). PTEN, PHLPP and caspase-3 were found to be decreased in pediatric 
AML patients compared to CD33+ healthy bone marrow cells (3 times (p>0.05), 10 
times (p>0.05) and 3 times (p>0.05) respectively). In order to characterize PHLPP 
gene, the expression of its four major domains (PH domain, LRR, PP2C-like 
catalytic core, and PDZ binding motif) were studied. Expressions of PH domain, 
PP2C-like catalytic core domain and PDZ binding domain were detected in both, 
pediatric AML patients and control group. Interestingly, expression of LRR domain in 
AML patients was not detected. PHLPP mRNA covering the region between exon 2 
to exon 17 was amplified by conventional PCR in pediatric AML samples lacking 
LRR domain expression, three different transcript variants varying between 1800-
5000 bps were identified. Direct sequencing results revealed a single nucleotide 
change in exon 5 at position 55 in those patients. Additionally, further studies were 
performed on the expression of four major functional PHLPP domains in various 
 
xviii 
tumour tissues (colon, stomach, pancreas and breast tumours). LRR domain 
expression could not be determined neither in pediatric AML samples nor in tumour 
samples. Moreover, PP2C like catalytic core expression was found to be lost in 
tumour samples. Recently, the loss of PHLPP expression in colon tumour tissues 
was also reported by Liu et al. (2008). Our results are in concordance with recent 
findings. Furthermore, PHLPP mRNA transcript variants different than those 
observed in pediatric AML samples were detected in tumour samples. Western blot 
analysis results also confirmed the loss of intact PHLPP expression in pediatric AML 
patients and tumour samples. This is the first study evaluating sequence variations 
together with the expression of PHLPP functional domains. It can be proposed that 
PHLPP gene might act as a tumour suppressor in AML leukomogenesis and 
tumorigenesis. This can provide an important guidepost for the development of 
appropriate diagnostic and therapeutic tools. The role of epigenetic regulation in 
cancer might explain the presence of PHLPP transcript variants in pediatric AML 
and different tumour tissues. Therefore, the possible underlying mechanisms need 
to be further studied. 
 
 
 
xix 
PI3K/AKT SĠNYAL ĠLETĠ YOLAĞININ PEDĠATRĠK AKUT MYELOĠD LÖSEMĠDEKĠ 
REGÜLASYONU: YENĠ BĠR TÜMÖR BASKILAYICI GEN PHLPP 
ÖZET 
Upregüle edilmiĢ fosfoinositid-3-kinaz (PI3K)/Akt yolağının, Akut Myeloid Lösemi 
(AML) patogenezinde ve hastalığın ilerlemesinde rol oynadığı bilinmektedir. Ayrıca, 
bu yolağın upregülasyonunun AML vakalarındaki genel sağ kalımı belirgin bir 
Ģekilde azalttığının gösterilmesi bu sinyal ileti kaskadını AML‘ye karĢı yeni terapötik 
stratejiler geliĢtirilmesinde, önemli bir hedef haline getirmiĢtir. Akt sinyal ileti yolunun 
terminasyonu, Akt defosforilasyonu ile gerçekleĢmektedir ve bundan baĢlıca iki 
protein sorumludur. Bu proteinler, PTEN ve yeni tanımlanmıĢ bir protein fosfataz 
olan PHLPP‘dir. PTEN, Akt aktivasyonunu, Akt‘yi aktifleyen ikincil mesajcıyı ortadan 
kaldırarak engellerken, PHLPP, Akt inaktivasyonunu, Akt‘nin hidrofobik motifini 
direkt olarak defosforile ederek gerçekleĢtirir. Yapılan çalıĢmalar sonucu, belli 
tümörlerin PTEN‘in çok fazla eksprese olmasına veya PI3 kinaz inhibitörlerine 
duyarlı olmadığı bildirilmiĢtir. Ayrıca PHLPP‘ nin ekspresyon seviyesinin kolon 
kanseri ve glioblastoma hücre soylarında, 13q14 delesyonu taĢıyan kronik lenfoid 
lösemi hastalarında ve kolon tümöründe azaldığı önceki çalıĢmalarda gösterilmiĢtir. 
Bu sonuçlar yeni bir tümör supresör olarak önerilen PHLPP‘nin Akt sinyal ileti 
yolundaki rolüne önem kazandırmakta ve PHLPP‘ yi yeni anti-kanser stratejilerinin 
geliĢtirilmesi için ilginç bir hedef haline getirmektedir. PHLPP, amino-terminal PH 
bölgesi, lösin yönünden zengin tekrar bölgesi (LRR), PP2C-benzeri katalitik merkez 
ve PDZ bağlanma bölgesi olmak üzere dört temel fonksiyonel bölge içerir. PHLPP 
geni için tanımlanmıĢ mutasyon henüz bulunmamaktadır. Bu çalıĢmada, PHLPP 
gene varyasyonları ve dört temel fonksiyonel PHLPP gen bölgesi ekspresyonları 
PI3K/Akt sinyal ileti yolağı genlerinden; Akt-1, PTEN ve kaspaz-3 gen ekspresyon 
seviyeleri ile birlikte incelenmiĢtir. Dört temel bölgeyi kodlayan 11 ekzonun pediatrik 
AML hastalarındaki mutasyon taraması DHPLC analizi ve direkt dizileme yöntemi ile 
gerçekleĢtirilmiĢtir. Bulunan PHLPP geni varyasyonları Ģunlardır: ekzon 2; 59insA 
(5.2%), 60C>T (2.8%), 77C>A (2.8%) ve 109A>T, ekzon 3; 289C>A (7.8%), 
352C>A (7.8%) ve 343insA (2.8%), ekzon 5; 599insA (47%), ekzon 14;  1980T>C 
(5.2%) ve 1992T>C (5.2%), ekzon17; 3280C>A (13.1%),  3302insA (13,1%), 
3303T>C (13.1%), 3407insA (5.2%) ve 3611insC (7.8%). Ekspresyon çalıĢmaları 
pediatrik AML hastaları ve kontrol grubunu oluĢturan, sağlıklı bireylere ait CD33+ 
kemik iliği hücrelerinde qRT-PCR yöntemi ile gerçekleĢtirilmiĢtir. Sonuçlar, Akt sinyal 
ileti yolağının hasta grubunda upregüle olduğunu göstermiĢtir (OR=4.4 95% CI= 
0.04-2.9, p=0.06). Bunun yanı sıra, PTEN, PHLPP ve kaspaz-3‘ün ekspresyonunun 
pediatrik AML hastalarında CD33+ sağlıklı kemik iliği hücrelerindekine göre daha az 
olduğu tespit edilmiĢtir (sırasıyla 3 kat (p>0.05), 10 kat (p>0.05) ve 3 kat (p>0.05)). 
PHLPP‘nin dört temel bölgesinin ekspresyon çalıĢmaları sonucunda ise, PH, PP2C-
benzeri katalitik merkez ve PDZ bağlanma bölgelerinin hasta ve kontrol gruplarında 
ekspresyonlarının olduğu bulunmuĢtur. Ancak LRR bölgesinin ekspresyonu 
hastalarda gözlemlenmemiĢtir. Bunun yanı sıra LRR bölgesi ekspresyonunun 
görülmediği hasta örneklerine ait PHLPP mRNA‘ sının ekzon 2 ve ekzon 17 
bölgeleri arası standart PCR yöntemi ile çoğaltılmıĢ ve boyları 1800-5000 bç 
arasında değiĢen üç farklı transkript varyantı tespit edilmiĢtir. Bu hastalara ait 
örneklerde direkt dizileme yöntemi ile ekzon 5 pozisyon 55‘ te tek baz değiĢikliği 
bulunmuĢtur. Ayrıca dört temel fonksiyonel PHLPP bölgesi ekspresyonuna kolon, 
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mide, pankreas ve meme tümörü dokularında da bakılmıĢtır. LRR bölgesinin 
ekspresyonunun tümör dokularında da olmadığı tespit edilmiĢtir. Pediatrik AML 
hasta örnekleriyle gerçekleĢtirilmiĢ ekspresyon çalıĢmalarının sonuçlarından farklı 
olarak, PHLPP‘nin PP2C-benzeri katalitik bölgesinin ekspresyonunun tümör 
dokularında olmadığı bulunmuĢtur. Liu ve arkadaĢlarının (2008) yaptıkları yeni 
çalıĢmada, kolon tümörü dokularında PHLPP ekspresyonunun olmadığı 
belirlenmiĢtir. Bu sonuçlar bizim çalıĢmamızın bulgularıyla da tutarlılık 
göstermektedir. PHLPP transkriptinin çoğaltılmasına yönelik yapılan çalıĢmalar 
sonucunda ise tümör dokularında, pediatrik AML hastalarında gözlemlenenlerden 
farklı PHLPP transkript varyantları görülmüĢtür. Western blot analizi sonuçları da 
eksiksiz PHLPP ekspresyonunun pediatrik AML hastalarına ait örneklerde ve tümör 
dokularında olmadığını göstererek gen ekspresyon çalıĢma sonuçlarını konfirme 
etmiĢtir. Bu çalıĢma PHLPP geninin sekans varyasyonlarının ve beraberinde 
ekspresyon seviyelerinin araĢtırıldığı ilk çalıĢmadır. ÇalıĢmanın sonuçları, PHLPP 
geninin AML lökomogenezinde ve tümörigenezde bir tümör supressör olarak rol 
oynayabileceğini ve bunun kanserin diagnoz ve tedavisine yönelik yöntemler 
geliĢtirilmesinde kullanılabileceğini düĢündürmektedir. Pediatrik AML hasta 
örneklerinde ve farklı tümör dokularında tespit edilen PHLPP transkript 
varyantlarının varlığı, kanser oluĢumu ve ilerleyiĢinde rol oynayan epigenetik 
regülasyonlar ile açıklanabilir. Bu bağlamda ileriki çalıĢmalarda farklı transkript 
varyantlarının oluĢumu altında yatan mekanizmalar araĢtırılmalıdır.  
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1. INTRODUCTION 
1.1 Haematopoiesis 
Blood contains many types of cells with very different functions, ranging from the 
transport of oxygen to the production of antibodies. All blood cells, however, have 
certain similarities in their life history. They all have limited life-spans and are 
produced throughout the life of animal [1]. The production of blood cells is an 
enormous task. The normal adult produces about 2.5 billion erythrocytes, 2.5 billion 
platelets and 1.0 billion granulocytes per kilogram of body weight daily. This number 
can be increased dramatically in response to various stresses, such as anaemia, 
bleeding or immunologic challenge. Since mature haematopoietic cells have a 
limited lifespan and no capacity for self-renewal, all of the circulating cells in the 
bloodstream are continually replaced by pluripotent haematopoietic stem cells 
(HSCs). These cells differentiate to form the mature cells of the haematopoietic 
system through a process termed haematopoiesis [2]. The multipotent stem cell 
normally divides infrequently to generate either more multipotent stem cells, which 
are self-renewing, or committed progenitor cells, which are limited in the number of 
times that they can divide before differentiating to form mature blood cells. The 
progenitors become more specialized in the range of cell types that they can give 
rise to as they go through their divisions (Figure 1.1) [1]. 
 
Figure  1.1 :  Heamatopoiesis: A schematic representation of the pathways leading 
             to the production of the mature cells of the haematopoietic system [1]. 
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The maintenance of the haematopoietic system requires a flexible control 
mechanism that is able to keep the correct cellular balance. To sustain this balance 
it would respond to various physiological stresses such as bleeding or infection. 
Therefore the control system requires both positive signals to initiate cellular 
production and negative feedback to keep the levels of cellular output in check. In 
order to maintain the appropriate balance of cellular production, haematopoiesis is 
controlled at two main levels: (i) through a series of humoral regulators known as 
cytokines and growth factors that are secreted by various cell types into the 
bloodstream and may act at distant sites in the body; and (ii) locally by cells in the 
microenvironment of the marrow known as stromal cells and haematopoietic cells. 
Disruption of the control of hemopoiesis can result in hemoproliferative disorders or 
leukemia, the malignant transformation of blood cells, that are often characterised 
by uncontrolled proliferation and deficient cellular differentiation [3]. 
1.2 Leukomogenesis 
It has been hypothesized that carcinogenesis, and for that matter, leukomogenesis, 
arises from neoplastic stem cells. Leukemia stem cells (LSC) exhibit characteristics 
similar to those of normal HSCs. Like normal HSCd, LSCs are quiescent and have 
self-renewal and clonogenic capacity. They are thought to arise from normal stem 
cells through the accumulation of oncogenic insults [4], [5]. It has been also 
suggested that LSCs may arise from differentiated progenitor cells that have 
reacquired the capacity for self-renewal [6-8]. Like normal HSCs, LSCs give rise to 
differentiated daughter cells that lose their self-renewal capacity. However, defects 
in their cellular machinery usually eliminate their ability to differentiate fully into 
morphologically and phenotypically mature cells. As a result, the leukemic 
population consists of undifferentiated and variably differentiated leukemia cells. The 
degree of differentiation of leukemia cells has traditionally formed the basis of the 
morphologic classification of leukemias [9, 10]. It is also to mention that, since LSCs 
are quiescent like normal HSCs, they do not respond to cell cycle specific cytotoxic 
agents used to treat leukemia and so contribute to treatment failure. These cells 
may undergo mutations and epigenetic changes, further leading to drug resistance 
and relapse. It has been also suggested that mature leukemia cells may acquire 
LSC characteristics, thereby evading chemotherapeutic treatment and sustaining 
the disease. Ongoing studies are likely to identify the molecular mechanisms 
responsible for LSC characteristics and lead to novel strategies for eradicating 
leukemia. 
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The studies done to understand the molecular mechanisms underlying the 
malignant transformation of many cell types have shown that mutations or 
deregulation of a wide spectrum of molecules acting at cellular sites ranging from 
the cell surface to the nucleus are implicated in tumorigenesis [11]. Moreover, 
results of studies combinating random mutagenesis screens and targeted amino 
acid substitutions in cellular genes, have revealed several mechanisms by which the 
qualitative properties of receptor signalling or the normal ligand-control of receptor 
function can be altered in leukemogenesis [12].   
1.3 Acute Myeloid Leukemia  
Leukemias have traditionally been classified and treated on the basis of phenotypic 
characteristics, such as morphology and cell-surface markers, and cytogenetic 
abberrations. 
Acute Myeloid Leukemia (AML) is accepted as a heterogenous group of malignant 
hematopoietic disorders. It has been recognized that like solid tumours, AML 
consists of a heterogeneous population of cells with a small percentage of 
noncycling, quiescent cells. AML is further characterized by uncontrolled 
proliferation of clonal neoplastic cells and accumulation of blasts with an impaired 
differentiation program in the bone marrow (Figure 1.2). These blast cells can be 
found blocked at various maturation steps and are resistant to cell death [13].  
 
            Normal Haematopoiesis                     Haematopoiesis in the case of AML 
Figure  1.2 : Normal haematopoiesis versus haematopoiesis in AML [14]. 
AML has 9 subgroups according to French-American-British (FAB) Classification 
which is based on the type of cell from which the leukemia developed and how 
mature the cells are (Table 1.1). In this manner, microscopic images of the leukemia 
cells after routine staining builds up largely the basis of this classification.    
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Table 1.1 : French-American-British (FAB) Classification of Acute Myeloid Leukemia    
                (AML) 
FAB 
subtype 
Name Cytogenetic 
remarks 
Approximate 
% of adult 
AML patients 
Prognosis 
compared to 
average for AML 
M0 Undifferentiated acute 
myeloblastic leukemia 
t(10;11) 5% Worse 
M1 Acute myeloblastic 
leukemia with minimal 
maturation 
Trizomy 11 15% Average 
M2 Acute myeloblastic 
leukemia with maturation 
t(8;21) 25% Better 
M3 Acute promyelocytic 
leukemia 
t(15;17) 10% Best 
M4 Acute myelomonocytic 
leukemia 
t(8;16) 20% Average 
M4eos Acute myelomonocytic 
leukemia with 
eosinophilia 
inv(16) 5% Better 
M5 Monocytic leukemia 11q23 10% Average 
M6 Acute erythroid leukemia t(3;5) 5% Worse 
M7 Acute megakaryoblastic 
leukemia 
— 5% Worse 
Overall incidence of AML has been reported to be stable or slowly increasing over 
the last 15-20 years. Despite considerable advances in the diagnosis of the different 
AML subtypes and progress in therapeutic approaches, current chemotherapies 
produce only initial remission, so that most patients will relapse and die from the 
disease. Therefore, there remains a need for new, rationally designed, minimally 
toxic, effective therapies for AML [13]. In this manner, new therapeutic targets has to 
be determined to eradicate AML. 
A ‗two hits‘ model has suggested that AML development requires multiple genetic 
changes that deregulate different cell programs [15]. Transcription factor fusion 
proteins such as AML1/ETO, PML-RARα, CBFβ/MYH11 or MLL/AF9 block myeloid 
cell differentiation by repressing target genes, thus providing one necessary event 
for leukemogenesis [16,17]. As second necessary event, disordered cell growth and 
upregulation of cell survival genes, is proposed. Mutations in growth regulatory 
genes such as FLT3, Ras and c-Kit are common in AML patients. These two 
classes of molecular events are highly interdependent.Changes in the transcriptional 
control in hematopoietic cells modify the arrays of signal transduction effectors 
available for growth factor receptors, whereas activating mutations in signal 
transduction molecules induce alterations in the activity and expression of several 
transcription factors that are essential for normal myeloid differentiation [18-20].  
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1.4 Phosphoinositol-3-kinase PI3K/Akt Pathway Human Cancer 
Carcinogenesis is the result of a disturbed balance between cell division and growth 
on one hand, and programmed cell death (i.e., apoptosis) on the other. This balance 
is impaired when proteins and signalling pathways regulating cell growth, 
differentiation and development undergo oncogenic changes .  
The phosphoinositide-3-kinase (PI3K)/Akt signaling network is crucial to widely 
divergent physiological processes that include cell cycle progression, differentiation, 
transcription, translation and apoptosis. Activation of this signalling pathway 
promotes cell survival and cell growth. As mentioned before, the balance between 
cell survival and apoptosis critically controls normal cell growth. Akt/Protein kinase B 
(PKB) regulates this balance through a phosphorylation cascade that primarily alters 
the function of transcription factors that regulate pro- and antiapoptotic genes. Upon 
activation, Akt delivers survival signals by inhibiting pro-apoptotic molecules such as 
Bad, Caspase-9, IkB kinase (IKK) and forkhead transcription factors. The PI3K/Akt 
signalling pathway is targeted by genomic abnormalities including amplification, 
mutation and rearrangement more frequently than any other pathway in human 
cancer, with the possible exception of the p53 and retinoblastoma pathways. 
Activation of PI3K/Akt signaling results in disturbance of control of cell proliferation 
and apoptosis, ensuing in competitive growth advantage for tumor cells [21-23]. 
Constitutive activation of PI3K/Akt pathway has been implicated in the both the 
pathogenesis and the progression of a wide variety of neoplasias. Furthermore, 
PI3K/Akt axis upregulation is asserted to play a major role not only in tumour 
development but also in the tumours potential response to cancer treatment [24].  
Overexpression of Akt/PKB was demonstrated to be an early event in colorectal 
carcinogenesis [25]. Furthermore, in gastric carcinomas high levels of Akt 
expression was found [26]. It has been also shown that overexpression of Akt 
contributes to the malignant phenotype of a subset of human pancreatic cancers 
[27]. Also, in breast tumours phosphorylated Akt in active form was associated with 
larger tumours and a reduced disease-free survival [28].  In addition to Akt 
expression levels contributing to carcinogenesis, downstream of PI3K are other 
molecules regulating this pathway, such as PI-3,4,5-P3 phosphateses. PTEN 
(Phosphatase and tensin homologue deleted on chromosome 10; also referred to as 
MMAC1, mutated in multiple advanced cancers 1) is a phosphatase with dual 
activity on lipids and proteins. It was originally identified as a tumour-suppressor 
gene. Its main physiologic lipid substrate is PI(3,4,5)P3, i.e., the PI3K product. 
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PTEN dephosphorylates  PI(3,4,5)P3 and in this way acts as a negative regulator for 
PI3K induced signalling [24]. Studies on PTEN overexpression in different cell lines 
suggested that it acts as a tumour suppressor by inhibiting cell growth and 
enchancing cellular sensitivity for apoptosis and anoikis. PTEN has been reported to 
be frequently mutated in advanced stages of several human tumours, notably in 
glioblastoma and prostate cancers [29, 30]. In addition, PTEN mutations in germ cell 
lines result in the rare hereditary syndrome referred to as Cowden`s disease, which 
is associated with a higher risk for development of malignant tumours, notably 
breast cancer [31]. Since, PTEN negatively regulates Akt activation through 
PI(3,4,5)P3 dephosphorylation, PTEN activity loss or impairment leads to permanent 
PI3K/Akt pathway activation.   
1.5 PI3K/Akt Pathway in Acute Myeloid Leukemia   
Studies showed that PI3K/Akt signaling is frequently activated in AML patient blasts 
and strongly contributes to proliferation, survival and drug resistance of these cells 
[32-35]. Moreover, both the disease-free survival and overall survival has been 
reported to be significantly shorter in AML cases with upregulated PI3K/Akt pathway 
[36]. Upregulation of the PI3K/Akt network in AML may be due to several reasons, 
including FLT3, Ras or c-Kit mutations, which are common in AML patients. In vitro 
studies including small molecules designed to selectively target key components of 
this signal transduction cascade have shown that apoptosis is induced and/or 
conventional drug sensitivity is markedly increased  in AML blasts. Considering 
these findings, PI3K/Akt pathway is suggested to represent a valid target for 
innovative therapeutic treatments of AML patients and inhibitory molecules are 
currently being developed for clinical use either as single agents or in combination 
with conventional therapies. 
1.6 Activation of PI3K/Akt Pathway: 
The large family of PI3K lipid kinases in mammalian cells has been categorized into 
3 classes, referred to as I, II and III. This classification is based on molecular 
structure and substrate specificity. Class I PI3Ks are the best understood ones and 
are key players of multiple intracellular signaling networks that integrate a wide 
variety of signals, engaged by many polypeptide growth factors. Growth factor 
receptors drive activation of class I PI3Ks either directly or via associated tyrosine 
kinases, heterotrimeric G proteins or Ras. Class I PI3K preferred in vivo substrate is 
phosphatidylinositol 4,5 bisphosphate (PtdIns(4,5)P2), which is phosphorylated to 
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yield phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3). The 
adaptor/regulatory subunits act to localize PI3K to the plasma membrane by the 
interaction of their Src homology 2 (SH2) domains with phosphotyrosine residues in 
activated receptors. They also serve to stabilize p110 and to limit its activity. Insulin 
and some growth factors preferentially signal through p110β [37].  
Akt, a serine/threonine protein kinase also known as protein kinase B (PKB), is the 
mammalian homolog of the transforming viral oncogene v-Akt that causes murine T-
cell lymphoma. Akt belongs to the cAMP-dependent, cGMP-dependent protein 
kinase C (AGC) family of protein kinases. Akt is known to include 3 closely related, 
highly conserved isoforms encoded by the following distinct genetic loci: Akt-1/α, 
Akt-2/β and Akt-3/γ.  Akt-1 is ubiquitously expressed at high levels with the 
exception of the kidney, liver and spleen. Akt-2 expression varies between different 
organs, with higher expression levels in the skeletal muscle, intestinal organs and 
reproductive tissues. Akt-3 is not detected in several tissues where Akt-1 and Akt-2 
are abundantly expressed, but it is relatively highly expressed in the brain and testis.  
Akt is activated by growth factors and other stimuli that cause generation of the lipid 
second messenger phosphatidylinositol-3,4,5-triphosphate (PtdIns P3) through 
activation of PI3K. Akt contains an NH2-terminal pleckstrin homology (PH) domain, 
which interacts with the phosphorylated lipid products of PI3K (mainly PtdIns 
(3,4,5)P3 and, to a lesser extent, phosphatidylinositol 3,4 bisphosphate (PtdIns 
(3,4,)P2)) synthesized at the plasma membrane. This lipid product places Akt to the 
membrane by engaging its PH domain, which results in a conformational change 
and enables the activation loop of the kinase to be phosphorylated on Thr308 by 
phosphoinositide-dependent protein kinase-1 (PDK-1, which also requires 3-
phosphorylated inositol lipids for activation and plasma membrane translocation) 
and at Ser 473 in the C-terminal hydrophobic motif by a kinase (often referred to as 
PDK-2). Candidate PDK-2s include integrin-linked kinase, DNA-dependent protein 
kinase and mitogen-activated protein kinase-kinase 2. After phosphorylation, Akt is 
locked in an active conformation and is released into the cytosol and nucleus where 
it phosphorylates substrates such as forkhead (FoxO) family members of  
transcription factors, proapoptotic factors BAD and caspase-9, nuclear factor-κB 
(NF- κB), and glycogen synthase kinase 3 β (GSK3 β). AKT also promotes cell 
growth by phosphorylating targets such as TSC2 (a negative regulator of mTOR) 
and mTOR itself.  [38, 39].  
Akt activity is modulated by a complex network of regulatory proteins that interact 
with the PH domain, or the kinase domain or the C-terminal of Akt [40]. One of these 
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proteins is heat-shock protein-90 (HSP-90), a molecular chaperone that forms a 
complex with the co-chaperone Cdc37. This complex binds a variety of proteins, 
including tyrosine and serine/ threonine protein kinases [41]. The HSP-90/Cdc37 
complex interacts with the Akt kinase domain. Therefore, small molecules capable 
of disrupting such an interaction may represent valid drugs to block Akt function.  
It should also be mentioned that PI3K/Akt signaling can be upregulated by many 
forms of cellular stress including heat shock, low pH, ultraviolet light, ischemia, 
hypoxia, hypoglycemia and oxidative stress [42]. Stress-induced PI3K/Akt 
upregulation is to be viewed as a compensatory protective mechanism which cells 
activate for escaping death. 
1.7 Mechanism of PI3K/Akt Signalling Pathway Activation in AML 
It has been highlighted that constitutive activation of PI3K/Akt signaling is a common 
feature of AML. From 50 to 70% of patients with AML display phosphorylation of 
both Thr 308 and Ser 473 Akt [43]. 
In about 15–25% of AML cases, N-Ras or K-Ras gene point mutations have been 
detected. These mutations cancel Ras intrinsic GTPase activity and lead to 
constitutive Ras activation with a consequent stimulatory effect on the PI3K/Akt 
pathway. It has been shown that Ras can activate the PI3K/Akt axis either by itself 
or through the Raf/MEK/ERK pathway. Furthermore, up to 20–25% of AML patients 
harbor internal tandem duplication (ITD) of the juxtamembraen domain of FLT3. This 
mutation results in ligand-independent dimerization of FLT3 and constitutive 
upregulation of its tyrosine kinase activity, ensuing in stimulation of downstream 
signaling pathways, including PI3K/Akt. Importance of FLT3-ITD in causing PI3K/Akt 
upregulation of mouse myeloid precursors is demonstrated by a study in which 
overexpression of FLT3-ITD cDNA resulted in constitutive activation of Akt, which 
phosphorylated and inhibited the transcription factor FoxO3 [44]. Besides, about 
80% of AML patients have blast cells that express c-Kit, another class III receptor 
tyrosine kinase for the stem cell factor (SCF) ligand [45]. Mutations in the 
extracellular or intracellular portions of c-Kit are known for activating PI3K/Akt. As to 
PTEN, it was observed that PTEN phosphorylation was present in approximately 
75% of AML patients. PTEN phosphorylation was significantly associated with Akt 
phosphorylation and with shorter overall survival [46]. It was demonstrated that 
phosphorylation at the C-terminal regulatory domain of PTEN stabilizes the 
molecule, but makes it less active towards its substrate, PtdIns (3,4,5)P3 so 
interferring with Akt phosphorylation [47]. Furthermore, PTEN expression has been 
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shown to be low or absent in some AML patients [34]. However, the level of PTEN 
expression did not always correlate with the degree of Akt phosphorylation [48].  
Other possible activation mechanisms of the PI3K/Akt cascade in AML cells have 
been proposed to include vascular endothelial growth factor (VEGF), which is a 
powerful angiogenic molecule for hematological malignancies. It behaves as a 
critical regulator of endothelial cell survival, motility and proliferation [49]. AML blasts 
synthesize and secrete VEGF and have demonstrable VEGF receptors, VEGFR-1 
and VEGFR-2 respectively [50]. Using human leukemic cell lines as experimental 
models, it has been shown that VEGF resulted in PI3K dependent Akt 
phosphorylation [51]. In addition, angiopoietins were detected to activate PI3K 
through an autocrine mechanism in AML blasts and human acute leukemia cell 
lines. Therefore, it was suggested that at least in some AML cases, upregulation of 
the PI3K/Akt axis might be due to an autocrine and/or paracrine production of 
angiogenic factors, such as VEGF and angiopoietins [52]. Besides, it was shown 
that activation of PI3K/Akt signaling was also dependent on autocrine secretion of 
insulin-like growth factor-1 (IGF-1). It is found that the growth of the AML blast cells 
is increased in vitro in response to IGF-1 stimulation [53]. Multiple large case-control 
studies have reported positive associations between high circulating levels of IGF-1 
and risk for different types of cancer [54]. Regarding malignant hematopoietic 
disorders, the role of IGF-1 in promoting proliferation, survival and drug resistance of 
multiple myeloma cells through PI3K/Akt signaling is well established [55]. Finally, 
interactions between very late antigen (VLA)-4 (α4β1 integrin) on leukemic cells and 
fibronectin on bone marrow cells has been shown to activate PI3K/Akt signal 
transduction network [56].  
Whatever the reason might be for PI3K/Akt activation, it is very important to consider 
that results of different studies have highlighted that upregulation of PI3K/Akt axis is 
present in the AML cell population, where it exerts a powerful prosurvival effect. This 
finding indicates that therapeutical targeting of the PI3K/Akt pathway has the 
potential for eradicating AML. 
1.8 Downstream Targets of PI3K/Akt Pathway 
1.8.1 Antiapoptotic Targets of PI3K/Akt Pathway 
Akt promotes cell survival by phosphorylating transcription factors that control the 
expression of pro- and anti-apoptotic genes. Akt either negatively affects factors that 
promote death gene expression or positively regulates factors inducing survival 
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genes. So, as a prototypic kinase, Akt promotes cellular survival to apoptotic insults. 
Akt enhances survival by directly phosphorylating key regulatory proteins of the 
apoptotic cascades. Akt phosphorylates Bad, a proapoptotic member of the Bcl-2 
family, at Ser 136. This phosphorylation event promotes Bad sequestration in the 
cytosol, thereby preventing Bad from interacting with either Bcl-2 or Bcl-XL at the 
mitochondrial membrane. The final effect is inhibition of apoptosis [57]. A similar 
negative regulation has been demonstrated for Yes-associated protein, whose 
phosphorylation by Akt leads to repression of p53 related transcription factor p73 
and reduced expression of the proapoptotic protein Bax [58].  
Most signals that lead to apoptosis do so by activating interleukin-1b converting 
enzyme (ICE)-like proteases termed caspases. Apoptosis is ultimately carried out by 
caspases that are common mediators both through the receptor mediated pathway 
containing members of the tumour necrosis factor (TNF) family and death receptors 
(APO-1/FAS and others), and the mitochondrial-mediated pathway involving BCL2, 
BCL-XI and cytochrome c release from the mitochondria and can be mediated by 
cytosolic BAX [59]. Caspases are synthesized as proenzymes. Cleavage at spesific 
aspartate residues converts the proenzymes into biologically active cysteine 
proteases.The activated caspases abolish the effect of substrates that protect 
cellular integrity, such as the DNA-repair enzyme poly(ADP-ribose) polymerase 
(PARP), and thereby induce apoptotic cell death. The activation of at least one 
caspase appears to be an essential step in cellular apoptosis. Consistent with this 
scheme, caspase 3 (CPP32, prICE, or Yama) has been found to be involved in 
leukemiacell apoptosis [60]. In addition, in previous studies it has been shown that 
IGF-I activated Akt resulted in inhibited caspase 3 activation, and these effects were 
reversed by the PI3K inhibitors [61].  
Furthermore, stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) is 
an important mediator of apoptosis in cells exposed to a variety of noxious stimuli, 
including chemotherapeutic drugs [62]. Akt interferes with SAPK/JNK signaling and 
negatively regulates it. In another mechanism towards apoptosis, Akt promotes 
phosphorylation and nuclear translocation of Mdm2, an E3 ubiquitin ligase which 
mediates ubiquitinylation and proteasome-dependent degradation of the p53 tumor 
suppressor protein, [63, 64] thereby downregulating p53 and antagonizing p53-
mediated cell cycle checkpoint. In that wise,  in some AML cases, p53 is regulated 
through PI3K/Akt dependent signaling and this pathway is proposed being a 
mechanism to promote resistance to cytotoxic agents [65]. 
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Akt also alters intracellular localization of FoxO family of transcription factors, 
formerly referred to as forkhead transcription factors, via phosphorylation. In the 
absence of Akt activation, FoxO proteins are predominantly localized in the nucleus 
where they are able to promote transcription of proapoptotic target genes such as 
Fas ligand (Fas-L) and Bim [66, 67]. In addition to downregulating FoxO activity, Akt 
is capable of upregulating nuclear factor-kappa B (NF-kB), which is deeply involved 
in the regulation of cell proliferation, apoptosis and survival [68, 69]. The survival-
promoting activity of NF-kB is mediated by its ability to induce expression of 
antiapoptotic proteins which oppose caspase activation. NF-kB function is regulated 
through its association with the inhibitory cofactor I-kB, which sequesters NF-kB. 
Phosphorylation of I-kB by upstream kinases, referred to as IKKs, promotes its 
degradation via the ubiquitinproteasome pathway. This, in turn, allows NF-kB 
nuclear translocation and upregulation of target genes [70]. Akt phosphorylates 
directly and activates IKKa and, more importantly, it is believed to be essential for 
IKK-mediated destruction of I-kB [71].  
1.8.2 PI3K/Akt Targets Acting on Cell Cycle Regulation 
Akt targets p27Kip1, a direct inhibitor of cyclin-dependent kinase (cdk) 2, one of the 
cdks responsible for the activation of E2F1 transcription factors that promote DNA 
replication. When phosphorylated by Akt on Thr 157, p27Kip1 mainly localizes to the 
cytoplasm where it cannot exert its inhibitory effect, so that cell proliferation is 
enhanced [71]. A direct relationship between cytoplasmic localization of p27Kip1 
and PI3K/Akt activation has been demonstrated in HL60 cells [72]. Moreover, 
cytoplasmic localization of p27Kip1 in AML blasts with upregulated Akt activity was 
demonstrated to be significantly associated with shorter disease-free and overall 
survival [73, 74]. Cyclin D1 levels were also found to be upregulated through 
PI3K/Akt signaling in leukemic cell lines [72]. This might depend on Akt-mediated 
inhibition of glycogen synthase kinase 3β (GSK3β), because cyclin D1 
phosphorylation by GSK3β results in its destabilization. Enhanced cell proliferation 
could also be a consequence of nuclear exclusion of FoxO factors, because these 
transcription factors, once in the nucleus, upregulate expression of three target 
genes which lead to G1/S arrest, p27Kip1, p21Waf/Cip1 and the retinoblastoma 
family member p130 [75-77]. Moreover, FoxO factors can also promote cell cycle 
arrest by repressing the expression of cyclin D1 and D2, two positive cell cycle 
regulators [78, 79]. 
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1.8.3 PI3K/Akt Targets Playing Role in Metabolism 
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase which 
regulates translation in response to nutrients/growth factors by phosphorylating 
components of the protein synthesis machinery, including p70S6 kinase (p70S6K, a 
ribosomal kinase) and eukaryotic initiation factor (eIF)-4E binding protein (4EBP)-1. 
Phosphorylation of 4EBP-1 results in release of the translation initiation factor eIF-
4E, allowing eIF-4E to participate in assembly of a translational initiation complex 
[80]. Furthermore, mTOR acts as a checkpoint sensor indicating to cells that there 
are sufficient nutrients available to proceed through the cell cycle [81, 82]. 
Therefore, mTOR regulates a variety of steps involved in protein synthesis, but in 
particular favors the production of key molecules such as c-Myc, cyclin D1 and 
ribosomal proteins [83]. p70S6K, which can also be directly activated by PDK-1, 
phosphorylates the 40s ribosomal protein, S6, leading to active translation of 
mRNAs [84]. By controlling protein synthesis, p70S6K and 4E-BP1 also regulate cell 
growth and hypertrophy, which are important processes for neoplastic progression. 
Therefore, even more distal steps in the PI3K/Akt pathway may have the potential to 
be exploited for cancer treatment. Akt-mediated regulation of mTOR activity is a 
complex multistep process. Akt inhibits tuberous sclerosis 2 (TSC2 or hamartin) 
function through direct phosphorylation [85]. Tuberous sclerosis 2 is a GTPase 
activating protein (GAP) that functions in association with the putative TSC1 (or 
tuberin) to inactivate the small G protein Rheb (Ras homolog enriched in brain) [86]. 
Tuberous sclerosis 2 phosphorylation by Akt represses GAP activity of the 
TSC1/TSC2 complex, allowing Rheb to accumulate in a GTP-bound state. Rheb-
GTP then activates the protein kinase activity of mTOR when complexed with the 
Raptor (regulatory-associated protein of mTOR) adaptor protein and mLST8. The 
mTOR/Raptor/mLST8 complex is sensitive to rapamycin and, importantly, inhibits 
Akt via a negative feedback loop which involves p70S6K [87]. The association of Akt 
with mTOR further includes the mTOR/Rictor (rapamycin-insensitive companion of 
mTOR)/mLST8 complex, which displays rapamycin-insensitive activity. Akt directly 
phosphorylates and activates mTOR, which is the only known example of Akt-
mediated phosphorylation resulting in substrate activation [88]. Besides, mTOR was 
found to be phosphorylated in AML blasts, along with its two downstream 
substrates, p70S6K and 4EBP-1, in a PI3K/Akt-dependent fashion [34]. 
Another Akt substrate important for metabolic function is GSK3β, which 
phosphorylates and inactivates glycogen synthase in response to insulin stimulation. 
When phosphorylated by Akt on Ser 9, GSK3β is downregulated [89]. Glycogen 
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synthase kinase 3 β is shown to be phosphorylated in AML cells with upregulated 
Akt function [46].  
Activation of PI3K/Akt pathway through mitogenic growth factor receptors and its 
effects on cell proliferation through downstream targets are represented in Figure 
1.3 given below.  
 
Figure  1.3 : Activation of PI3K/Akt pathway in AML and its downstream targets 
[38]. 
1.9 Negative Regulation of the PI3K/Akt Pathway 
The termination of Akt signaling is under the control of two key proteins: PTEN, a 
lipid phosphatase, that prevents activation by removing the second messenger that 
activates Akt, and PHLPP, a protein phosphatase, that inactivates Akt by direct 
dephosphorylation of the hydrophobic motif (Figure 1.4) [90]. 
PTEN (Phosphatase and TENsin homolog deleted on chromosome 10) is a dual 
specificity lipid and protein phosphatase that preferentially removes the 3-phosphate 
mainly from PtdIns (3,4,5)P3 but is also active on PtdIns (3,4,)P2, thereby 
antagonizing PI3K/Akt signaling network [91]. PTEN-inactivating mutations or 
silencing occur in a wide variety of human cancers (including glioblastoma, 
melanoma, prostatic and endometrium carcinomas) and this results in Akt 
upregulation [92]. Therefore, PTEN is a tumor suppressor acting upstream of Akt 
[93]. Two other phosphatases, SHIP-1 and SHIP-2 (for SH domain-containing 
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inositol phosphatases), are capable of removing the 5-phosphate from PtdIns 
(3,4,5)P3 to yield PtdIns (3,4,)P2. Whereas SHIP-1 is predominantly expressed in 
hematopoietic cells, SHIP-2 is more ubiquitous. However, their role on Akt function 
is not well understood, and in some cases they could not reverse Akt activation, 
something PTEN can do [94]. Protein phosphatase 2A (PP2A), which is rapidly 
emerging as a new oncosuppressor, [95] is capable of directly dephosphorylating 
and downregulating Akt, [96,97] whereas it was also indicated that Ser 473 
phospho-Akt is dephosphorylated by a PP2C family phosphatase, referred to as 
PHLPP, another candidate tumour suppressor [90]. 
 
Figure  1.4 : Negative regulation of Akt by two tumour suppressors; PTEN and  
  PHLPP [90]. 
Human PH domain and leucine rich repeat protein phosphatase, PHLPP, is a 1205 
residue protein and weighes 133564 Da. PHLPP is predicted to contain an amino-
terminal pleckstrin homology (PH) domain, a leucine-rich repeat region (LRR), a 
PP2C-like catalytic core, and a PDZ binding motif. The PDZ binding motif is 
asserted to be crucial for the biological function of PHLPP. It was shown that 
deletion of the 3 carboxy-terminal residues encoding this motif inhibits the ability of 
PHLPP to dephosphorylate Akt, to promote apoptosis, and to suppress tumors. PDZ 
domains can occur in one or multiple copies and are nearly always found in 
cytoplasmic proteins. They bind either the carboxyl-terminal sequences of proteins 
or internal peptide sequences. In most cases, interaction between a PDZ domain 
and its target is reported to be constitutive. However, agonist-dependent activation 
of cell surface receptors is sometimes required to promote interaction with a PDZ 
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protein. PDZ domain proteins are frequently associated with the plasma membrane, 
a compartment where high concentrations of phosphatidylinositol 4,5-bisphosphate 
(PIP2) are found. Direct interaction between PIP2 and a subset of class II PDZ 
domains has been demonstrated. Furthermore, the PDZ binding motif is conserved 
in lower organisms such as C. elegans and Drosophila unlike the PH domain, which 
is supposed to be added later in evolution and is not required for function. In general 
terms, PH domain is a domain of about 100 residues that occurs in a wide range of 
proteins involved in intracellular signalling or as constituents of the cytoskeleton. 
The function of this domain is not clear, but several putative functions have been 
suggested including; binding to the beta/gamma subunit of heterotrimeric G 
proteins, binding to lipids, e.g. phosphatidylinositol-4,5-bisphosphate, binding to 
phosphorylated Ser/Thr residues like Akt1 phosphorylated at Ser473 and Thr308, 
and attachment to membranes by an unknown mechanism. More to PHLPP 
functional domains, PP2C-like catalytic core refers to protein phosphatase 2C, 
which is a Mn++ or Mg++ dependent protein serine/threonine phosphatase. LRR are 
short sequence motifs present in a number of proteins with diverse functions and 
cellular locations. These repeats are usually involved in protein-protein interactions 
[90]. A significant role for LRR domain of LRRC4, a putative tumour supressor, has 
been reported in glioma cell proliferation. In the LRR cassette domain of LRRC4 the 
third LRR motif of the core LRR has been found to play a crucial role as a 
―proliferation-inhibition switch‖. Moreover, it is proposed that LRRC4 requires a 
functional LRR cassette domain to inhibit proliferation of glioma cells in vitro by 
modulating the extracellular signal-regulated kinase/protein kinase B/nuclear factor-
κB pathway [98]. Human PHLPP gene is located on 18q21.33 and comprises 17 
exons. Coding sequence for PH domain expands exon2, exon3, and exon4; for LRR 
exon5, exon6, and exon 7; for PP2C exon 14, exon15, exon16, and exon 17; and 
coding sequence for PDZ is included in exon 17 (Figure 1.5) [90].   
 
                                       exon 2         exon 5                  exon 14               exon 17 
                                         exon 3         exon 6                  exon 15 
                                           exon 4         exon 7                  exon 16 
                                                                                               exon 17 
Figure  1.5 : Coding regions for four major functional PHLPP domains [90]. 
PTEN has proven to be an archetypal tumor suppressor by its effects on the Akt 
signaling pathway. Nonetheless, there are abundant examples of Akt 
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phosphorylation being elevated in cancer cell lines having wild type PTEN. Thus, it 
is clear that other mechanisms causing elevation of Akt phosphorylation contribute 
to tumour progression. Gao et al. (2005) showed that PHLPP levels are markedly 
reduced in a number of colon cancer and glioblastoma cell lines. Moreover, 
reintroduction of PHLPP into a glioblastoma cell line that is wild type in PTEN 
decreased the growth rate of these cells by ~ 50%. The magnitude of this growth-
suppressive effect was similar to that observed after reintroduction of PTEN into 
glioblastoma cell lines defective in PTEN [99]. In addition, it has been reported that 
subcutaneous injection of glioblastoma cells transfected with PHLPP dramatically 
reduced the ability of these cells to induce tumors [90]. Recently, Liu et al. (2008) 
found loss of PHLPP expression in colon tumour tissues [100]. Also, PHLPP RNA 
was reported to be absent in ~ 50% chronic lymphocytic leukemia cases with 
deletion 13q14 [101]. 
To conclude, as it was demonstrated in a number of studies that certain tumors 
were insensitive to inhibitors of PI3 kinase and to the overexpression of PTEN, 
importance of PHLPP in AKT pathway regulation as a negative regulator and tumour 
suppressor emerges.  
1.10 Aim of the Study 
Acute myeloid leukemia (AML) is one of the most common and deadly forms of 
hematopoietic malignancies. The overall incidence of AML has been stable or slowly 
increasing over the last 15–20 years. The current chemotherapies produce only 
initial remission which emphasize the need for new, rationally designed, minimally 
toxic, effective therapies for AML. PI3K/Akt signaling is frequently activated in AML 
patient blasts and strongly contributes to proliferation, survival and drug resistance 
of these cells. The overactivated PI3K/Akt pathway represents potential therapeutic 
targets for AML. The inactivation of Akt is under the control of two key proteins: 
PTEN, a lipid phosphatase, that prevents activation by removing the second 
messenger that activates Akt, and PHLPP, a protein phosphatase, that inactivates 
Akt by direct dephosphorylation of the hydrophobic motif S473. Since there are 
abundant examples of elevated Akt phosphorylation level in cancer cell lines having 
wt PTEN, the role of PHLPP, referred to a novel tumor-suppressor, in Akt signaling 
emerges and makes PHLPP an attractive target for the development of novel 
anticancer strategies. 
This study aims to determine the role of Akt signaling pathway in pediatric AML and 
to demonstrate the importance of PHLPP and PTEN in the regulation of Akt 
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signaling pathway. Human PHLPP contains an amino-terminal PH domain, a 
leucine-rich repeat region (LRR), a PP2C-like catalytic core and a PDZ binding 
motif. So far, there are no described mutations in PHLPP gene. In this study, it is 
aimed to understand the architecture of PHLPP gene variations in pediatric AML 
patients. Molecular screening was performed for 11 exons covering the four 
domains of PHLPP gene in pediatric AML patients. The screening for the presence 
of a mutation was performed by Denaturing High Performance Liquid 
Chromatography analysis and mutation detection was accomplished by direct 
sequencing. To indicate the role of PHLPP in upregulation of Akt pathway in AML 
patients, first  Akt-1 expression was studied in pediatric AML patients as well in 
controls. Since upregulated Akt signalling is expected to reduce the caspase-3 gene 
expression, caspase-3 expression was also analysed in both patient and control 
group. To understand the importance of PTEN and PHLPP in Akt upregulation, their 
expression levels in patients were compared to their expression levels in controls. 
Also expression analysis of the exons covering the four functional domains of 
PHLPP was performed for molecular characterisation of PHLPP gene. In gene 
expression studies, expression levels of selected housekeeping genes -abelson, 
beta-2-microglobulin, cyclophilin- were studied in patients and controls to normalize 
the results. Expression of Akt, pAkt (Ser473), pAkt (Thr308), PTEN, and PHLPP 
was also checked at protein level to confirm the results of gene expression studies. 
For this purpose total proteins isolated from pediatric AML patients were studied via 
Western Blot Analysis. The phosphorylated Akt was studied with Ser473 and Thr308 
spesific antibodies separately, since PHLPP directly dephosphorylates Akt at 
Ser473 residue and so the role of PHLPP and PTEN in Akt dephosphorylation might 
be demonstrated. Since there is no previous data for molecular genetic 
characterisation of PHLPP gene, gene expression studies were performed in 
different tumour tissues (stomach, colon, pancreas, and breast) to obtain 
comperative data.   
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2. MATERIALS AND METHODS 
2.1 Materials and Laboratory Equipments 
2.1.1 Equipments 
The laboratory equipment used in this study is listed in Appendix A. 
2.1.2. Chemicals, Enzymes and Markers 
The chemicals, enzymes and markers used are given in Appendix B together with 
their suppliers. The compositions and preparation of buffers and solutions are given 
in Appendix C. 
2.1.3 Used Kits 
The kits used and their suppliers are given in Appendix D. 
2.1.4 Case and Control Group 
Study group is composed of 40 pediatric Acute Myeloid Leukemia (AML) patients 
newly diagnosed according to the French American British (FAB) classification. 
Diagnosis was based on peripheral blood and bone marrow examination for 
morphology, cytochemistry and immunophenotypic studies. The bone marrow 
samples of the patients used in this study were collected for diagnostic purposes in 
the first place. The age of the patients ranged from 17 months to 14 years with a 
median age of 8 years. There were 16 females and 22 males. Further information 
about patient group is listed in the table 2.1 given below. 
Control group used in gene expression studies was composed of CD33+ cells 
isolated from bone marrow samples of 5 healthy donors. In mutational analysis, 
control group was consisting of peripheral blood samples of 50 healthy controls. 
Human pediatric bone marrow was obtained from AML patients and control group 
after obtaining informed consent from the volunteers. The appropriate standards for 
human experimentation were followed, and the experimental design of this study 
has been reviewed and approved by the Ethics Review Committee  of the Medical 
Faculty of Istanbul University. 
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Table 2.1 : List of translocations, FLT3-ITD,FLT3-D835 mutations and Vascular 
 Endothelial Growth Factor Receptor 1 (FLT-1), Vascular Endothelial 
 Growth Factor Receptor 2 (KDR), Estrogen Receptor  Alpha (Erα), and      
 Estrogen  Receptor  Beta  (Erβ)  expressions  in pediatric  AML patient  
 group. 
Patients 
no 
Lineage T(15;17) T(8;21) inv(16) FLT3-ITD FLT3-D835 FLT-1 KDR ERα ERβ 
1 AML - - - - - - + + - 
2 AML - - - + - + + - - 
3 AML - - - - - - - + - 
4 AML - - - - - - - + - 
5 AML-M3 + - - - - - + + - 
6 AML + - - - - + - + - 
7 AML - - - - - - + + - 
8 AML M3 - - - - - + + + - 
9 AML M2 - - - - - - - + - 
10 AML M1 - + - - - + + - - 
11 AML M3 - - - - - + - - - 
12 AML M3 + - - - - - - - - 
13 AML + ND - - - - - - - 
14 AML M3 + ND - + - + + - - 
15 AML M2 - ND - + - + + - - 
16 AML M3 - ND - - - - - - - 
17 AML - ND - - - + + - - 
18 AML M7 - ND - - - + - - - 
19 AML - ND - - - - - - - 
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Table 2.1 : (continued) List of translocations, FLT3-ITD, FLT3-D835  mutations  and  
Vascular Endothelial Growth Factor Receptor 1 (FLT-1), Vascular 
Endothelial Growth Factor Receptor 2 (KDR), Estrogen Receptor   Alpha 
(Erα), and Estrogen Receptor Beta (Erβ) expressions in  pediatric  AML 
patient group. 
Patients 
no 
Lineage T(15;17) T(8;21) inv(16) FLT3-ITD FLT3-D835 FLT-1 KDR ERα ERβ 
20 AML - ND ND - - + + - - 
21 AML - ND ND - + - - + - 
22 AML ND ND ND - - + - + - 
23 AML M3 + ND ND - - + - + - 
24 AML M3 ND ND ND - - + - + - 
25 AML M3 ND ND ND + - - - + - 
26 AML M0 - - - - - + + - - 
27 AML M2 - - - - - + - - - 
28 AML M7 - - - - - + - + - 
29 AML M0 - - - - - + + + - 
30 AML M2 - - - - - + + + - 
31 AML M3 - - - - - - - + - 
32 AML M1 - - - - - + + + - 
33 AML M3 - - - - - - + + - 
34 AML M5 - - - - - + + + - 
35 AML M3 - - - - - + - - - 
36 AML M3 - - - + - - + + - 
37 AML M3 - - - - - - + + - 
38 AML M3 - - - + - - - - - 
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2.1.5 Tumour Tissues  
Breast, stomach, colon and pancreas tumour tissue (10 of each) samples were used 
in gene expression studies. 
2.2 Collection and Storage of Blood Samples and Tumour Tissues 
The bone marrow samples and peripheral blood samples are collected from the 
patients who came to the Medical Faculty of Istanbul University, Department of 
Pediatric Hematology and Oncology. The bone marrow and peripheral blood 
samples were collected in vacuum tubes containing EDTA. The samples were kept 
at +4 oC for short term storage (1/2 day).  
Tumour tissues were stored at -80oC for longer terms of storage (several months). 
2.3 Isolation of Bone Marrow and Peripheral Blood Leukocytes by Ficoll 
Gradient Centrifugation 
Leukocytes were isolated via applying Ficoll density gradient centrifugation. A 
volume of 2.5 ml Ficoll-Histopaque (Sigma) was put in a 10 ml glass tube. 
Subsequently, 5 ml of freshly drawn (maximum ½ day of storage at +4  oC) blood or 
bone marrow sample was poured into the tube. The mixture was centrifuged at 2000 
x rpm for 20 minutes at room temperature. Fractions were collected from the top 
with a Pasteur pipette (plasma and leukocytes). Leukocytes were washed twice with 
phosphate-buffered saline (PBS). For each washing step 3.5 ml of PBS was added 
onto the leukocyte pellet and the mixture was centrifuged at 2000 x rpm for 5 
minutes at room temperature. For long term storage (several months) leukocyte 
pellet was homogenized in 600 µl of solution D in a sterile tube and stored at -80 oC. 
Solution D contains Buffer RLT, which immediately inactivates DNases and RNases 
as well as proteases to ensure isolation of intact DNA, RNA, and proteins. 
2.4 CD33+ Cell Isolation on Magnetic Bead Columns 
CD33+ cells were fractioned from pediatric bone marrow samples obtained from 5 
healthy donors. Firstly, leukocytes were isolated from 5 ml of freshly drawn bone 
marrow sample by Ficoll Gradient Centrifugation as indicated above. Leukocyte 
pellet obtained after 2 washing steps with PBS was resuspended in 80 µl of MACS 
buffer (MACS BSA stock solution diluted with 1:20 autoMACS Rinsing solution). 20 
µl of CD33 MicroBeads (MACS) was added to this suspension and the mixture was 
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incubated at +4 oC for 15 min in order to magnetically label CD33+ cells. Then, the 
cells were washed by adding 2 ml of MACS buffer to the mixture and a following 
centrifugation step was accomplished at 2000 x rpm for 5 min at room temperature. 
The supernatant was pipetted off completely and the cells were resuspended in 500 
µl of MACS buffer. After the steps of magnetic labeling, magnetic separation was 
applied by using MiniMACS Column and MACS Separator (Miltenyi Biotec). The 
column was placed in the magnetic field of a MACS Separator. Next, the column 
was prepared by rinsing it with 500 µl of MACS buffer. The cell suspension was 
loaded onto the column. The magnetically labeled CD33+ cells were retained on the 
column and unlabeled cells which passed through were collected. The column was 
washed 3 times by adding 500 µl of MACS buffer each time once the column 
reservoir was empty. After 3 washing steps, the column was removed from the 
separator and placed on a sterile collection tube. 500 µl of MACS buffer was added 
onto the column. The fraction with the magnetically labeled cells was immediately 
flushed out by firmly applying the plunger supplied with the column. The purity of 
CD33+ cells eluted from the MACS column were checked by FACS scanning and 
CD33+ cell suspension in MACS buffer used in final elution was centrifuged at 
10,000 x rpm for 5 min at room temperature. The supernatant was pipetted off and 
the CD33+ cell pellet was resuspenden in 350 µl of  solution D and stored at -80 oC. 
2.5. Flow Cytometric Analysis of the Sorted Cells 
Flow cytometric analysis was performed to ensure the purity of the isolated CD33+ 
cells. Before analysis, the enriched CD33+ cells were labeled with FITC-conjugated 
anti-CD33 beads. Flow cytometric analysis was accomplished by BD 
FACSCalibur™ Flow Cytometer (Becton Dickinson). 
2.6 DNA, RNA, and Protein Isolation from Leukocytes  
For simultaneous purification of DNA, RNA, and protein from leukocytes stored in 
solution D, AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Germany) was used. 
Leukocytes in solution D were thawed and homogenized in Buffer RLT, which 
immediately inactivates DNases and RNases as well as proteases to ensure 
isolation of intact DNA, RNA, and proteins. The homogenate was then centrifuged at 
14,000 x rpm for 2 min at room temperature. The supernatant was then passed 
through an AllPrep DNA spin column which in combination with the high-salt buffer, 
allowing selective and efficient binding of genomic DNA. In this step DNA spin 
column was placed on a 2 ml collection tube and centrifugation was performed at 
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12,000 x rpm for 30 sec. The DNA spin column was put onto a new 2 ml collection 
tube and stored at +4 oC for further steps of DNA elution.  
For RNA purification, ethanol was added to the flow-through from the AllPrep DNA 
spin column in order to provide appropriate binding conditions for RNA (250µl of 
ethanol was added for 350 µl of solution D used for storage of leukocytes). The 
sample was then applied to a RNeasy spin column, where total RNA binds to the 
membrane and contaminants are washed away. RNeasy spin column was put onto 
a new 2 ml collection tube and centifuged at 12,000 x rpm for 15 sec. The flow-
through was transferred to a 2 ml tube for protein purification. 700 µl of  Buffer RW1 
was added to the RNeasy spin column and the column was centrifuged at 12,000 x 
rpm for 15 sec to wash the spin column. The flow-through was discarded. 500 µl of  
Buffer RPE was added to the RNeasy spin column and the column was centrifuged 
at 12,000 x rpm for 15 sec. The flow-through was discarded. This step was repeated 
twice. The RNeasy spin column was placed in a new 2 ml collection tube and 
centrifugation was carried out at 14,000 x rpm for 1 min. Afterwards, the RNeasy 
spin column was placed in a new 1,5 ml collection tube and 30 µl of RNase-free 
water was added to the spin column membrane. The column was let at room 
temperature for 1 min and then centrifuged at 12,000 x rpm for 1 min to elute total 
RNA. The flow-through was put into the column and the last centrifugation step was 
repeated in order to increase RNA yield.  
For total protein precipitation, 600 µl of Buffer APP was added to the flow-through 
from first centrifugation step of total RNA purification, where Buffer APP is an 
aqueous protein precipitation solution. The mixture was mixed vigorously by using 
vortex and let at room temperature for 10 min. The precipitated proteins are pelleted 
by centrifugation at 14,000 x rpm for 10 min. The supernatant was carefully 
decanted via pipetting it off. 500 µl of 70% ethanol was added to the protein pellet 
and this was followed by a centrifugation at 14,000 x rpm for 2 min. The supernatant 
was removed by using a pipet. Then, the protein pellet was dried at room 
temperature for 10 min. Intact total proteins were redissolved in 100 µl of Buffer 
ALO, which is compatible with SDS-PAGE. The suspension was incubated at 95 oC 
for 5 min to completely dissolve and denature the protein. Next, the sample was 
cooled to room temperature and centrifuged at 14,000 x rpm for 1 min to pellet any 
residual insoluble material. The supernatant was collected and stored in a sterile 2 
ml tube for further SDS-PAGE and Western Blotting studies. 
To purify genomic DNA, 500 µl of Buffer AW1 was added to the AllPrep DNA spin 
column stored for DNA elution in previous steps. After addition of Buffer AW1, the 
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column was centrifuged at 10,000 x rpm for 15 sec. The flow-through was discarded 
and the DNA spin column was placed in a new 2 ml collection tube.  500 µl of Buffer 
AW2 was added to the column and centrifuged at 14,000 x rpm for 2 min. The 
column was placed in a new 2 ml collection tube and centrifuged at 14,000 x rpm for 
1 min. Next, the column was placed in a new 1,5 ml collection tube and 100 µl of 
Buffer EB was added to the column membrane. After incubation at room 
temperature for 1 min, the column was centrifuged at 10,000 x rpm for 1 min to elute 
the DNA. The flow-through was added to the column membrane and following 
incubation at room temperature for 1 min, the column was centrifuged at 10,000 x 
rpm for 1 min to elute further DNA. 
The isolated stock of total DNA, RNA, and dissolved protein were quantified via 
NanoDropTM 1000 Spectrophotometer (Thermo Scientific) and kept at -80 °C for 
longer terms (several months) of storage. 
2.7. RNA Isolation from Leukocytes  
To purify high yields of total RNA to use in quantitative Real Time PCR studies, total 
RNA was isolated via using QIAamp RNA Blood Mini Kit (Qiagen) from low number 
leukocyte samples stored in solution D. Isolation was performed according to 
suppliers manual.  
Each of the leukocyte samples stored in 500 µl of solution D was transferred directly 
into a QIAshredder spin column (Qiagen) in a 2 ml collection tube and centrifuged at 
14,000 x rpm for 2 min. The column was discarded and homogenized lysate was 
saved. 1 volume (500 µl) of 70% ethanol was added to the homogenized lysate and 
mixed by pipetting. Then, the sample was transferred into a new QIAamp spin 
column in a 2 ml collection tube and centrifuged at 10,000 x rpm for 15 sec. The 
column was placed into a new 2 ml collection tube and 700 µl of Buffer RW1 was 
added to the column. Next, the column was centrifuged at 10,000 x rpm for 15 sec.  
The column was placed in a new 2 ml collection tube and 500 µl of Buffer RPE was 
put into the column. The column was centrifuged at 10,000 x rpm for 15 sec and the 
supernatant were discarded.  Then, 500 µl of Buffer RPE was added to the column 
membrane and the column was centrifuged at 14,000 x rpm for 3 min. The column 
was placed in a new 2 ml collection tube and centrifuged  at 14,000 x rpm for 1 min 
to eliminate the chance of possible Buffer RPE carryover. In the final step, the 
column was transferred into a 1.5 ml microcentrifuge tube and 30 µl of RNase-free 
water was added directly onto the column membrane. To elute total RNA, the 
column was centrifuged at 10,000 x rpm for 1 min. The purified total RNA was 
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quantified via NanoDropTM 1000 Spectrophotometer (Thermo Scientific) and kept at 
-80 °C for longer terms (several months) of storage. 
2.8 DNA, RNA, and Protein Isolation from Tumour Tissues 
To subsequentially purify DNA, RNA, and protein from tumour tissues, AllPrep 
DNA/RNA/Protein Mini Kit (Qiagen, Germany) was used. 30 mg of tumour tissue 
sample was firstly homogenized in 600 µl of TRIzol Reagent (Invitrogen). The 
homogenized samples were put into 1,5 ml microcentrifuge tubes and centrifuged at 
14,000 x rpm for 10 min. The supernatant was transferred into AllPrep DNA spin 
column (Qiagen) and the purification steps were carried on as indicated in section 
2.6.  
2.9 Quantification and Qualification of DNA 
The isolated stock of total DNA via AllPrep DNA/RNA/Protein Mini Kit 
(Qiagen,Germany) was quantified by applying NanoDropTM 1000 Spectrophotometer 
(Thermo Scientific). For each measurement 1µl of stock DNA was applied. As the 
blank solution Buffer EB (Qiagen) was used. The concentration and purity of the 
isolated DNA were calculated by using the absorbance values measured at 260, 
280 and 320 nm. The concentration of the DNA was calculated with the equation 2.1 
and the purity of the DNA samples were calculated with the equation 2.2 given 
below: 
 
                (2.1) 
 (2.2) 
In order to have a set of DNA samples that have the same DNA concentration (50 
ng/μL), dilutions from the stock DNA are prepared (working solutions).  
2.10. Quantification and Qualification of RNA 
The concentration of RNA was determined by NanoDropTM 1000 Spectrophotometer 
(Thermo Scientific) measurement of the absorbance at 260 nm (A260). An 
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absorbance of 1 unit at 260 nm corresponds to 40 µg of RNA per ml of water (in pH 
7 conditions). For each measurement 1µl of isolated RNA stock diluted in 30 µl of 
RNase-free water was applied. As the blank solution RNase free water was used. 
The concentration of the sample was calculated according to the formula 2.3 given 
below: 
Concentration (µg/ml) = 40µg x A260 x Dilution factor                                            (2.3) 
Also measurement was performed at A280 to check DNA contamination. The purity of 
RNA was estimated via calculating the A260/A280 ratio. 
Qualification of purified RNA was made via RNA Gel Electrophoresis. For this 
purpose 1% agarose gel was prepared by adding 0.5 g of agarose into 50 ml of 1x 
TAE buffer. The mixture was heated in a microwave oven to melt the agarose and 
then cooled to 65 0C at room temperature. 2 µl (0.4 μg/mL) of ethidium bromide  was 
added to the mixture. All components were mixed and gel was poured onto gel 
support. Gel was left to polymerize at room temperature. Before loading the samples 
the gel tank was filled with 1x TAE Gel Running Buffer. 5 µl of RNA was mixed with 
1µl of 6x Loading Dye (Fermentas) and loaded onto the agarose gel in TAE buffer. 
The RNA samples were run at 90 V. The detection was accomplished via UV lamp. 
2.11 Quantification of Proteins 
2.11.1 Measurement by NanoDropTM 1000 Spectrophotometer 
The protein concentration was first checked by NanoDropTM 1000 
Spectrophotometer (Thermo Scientific) measurement of the absorbance at 280 nm 
(A280). 
2.11.2 Bradford Assay  
For more accurate determination of protein concentration Bradford Assay was 
performed prior the use of the proteins by SDS-PAGE and Western Blot Analysis.  
Use of Coomassie Blue Dye in a colorimetric reagent for the detection and 
quantification of total protein was first described by Dr. Marion Bradford in 1976. In 
the acidic environment of the reagent, protein binds to the coomassie dye, which 
results in a spectral shift from the reddish/brown form of the dye (absorbance max. 
at 465 nm) to the blue form of the dye (absorbance max. at 610 nm). The difference 
between the two forms of the dye is greatest at 595 nm, thus it is the optimal 
wavelength to measure the blue color from the coomassie dye-protein complex. 
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Besides, the blue color can be measured at any wavelength between 575 nm and 
615 nm. Bradford protein assay has been associated with the presence of certain 
basic amino acids (primarily arginine, lysine and histidine) in the protein. Van der 
Waals forces and hydrophobic interactions also participate in the binding of the dye 
by protein. The number of coomassie dye ligands bound to eache protein molecule 
is approximately proportional to the number of positive charges found on the protein. 
Free amino acids, peptides and low molecular weight proteins do not produce color 
with coomassie dye reagents. 
The assay is performed at room temperature. The measurement was accomplished 
at 595 nm by using a 96 well plate. For measurement in a working range 100-1500 
µg/ml, protein samples of 10 µl was prepared from protein stocks in a 1:10 ratio, 
using distelled water as diluent. Bovine serum albumin (BSA) dilutions in a range of 
28 µg-1,25 µg/ 20 µl diluted with distilled water were used as protein standarts. 5 µl 
of BSA standards and protein samples were loaded in a 96 well plate. 200 µl of 
Bradford Reagent was added onto each well and homogenized via pipetting. After 
incubation at room temperature for 5 min, the absorbance values were measured at 
595 nm by Microplate reader 3550-UV (Biorad).  
2.12 Mutation Analysis 
2.12.1 Template DNA 
Purified DNA samples from 38 pediatric AML patients and 30 healthy controls were 
used in mutational analysis of PHLPP gene coding regions for four major functional 
domains. 
2.12.2 Primer Design 
The coding regions for four major functional domains of PHLPP gene were targeted 
for mutational analysis (Fig. 2.1). For this purpose, exonic sequences coding for PH-
domain, Leucine-rich Repaet (LRR) domain, PP2C-like catalytic core, and PDZ-
binding core were selected and primers were designed to amplify the coding 
regions. 
Coding region for PH-domain encompasses exon 2, 3, and 4; for LRR-domain exon 
5, 6, and 7; for PP2C-like catalytic core exon 14, 15, 16, and 17; for PDZ binding 
region exon 17. Primer sequences to amplify coding regions for four functional 
domains were designed using the Primer3 software (available online at 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primers with length 
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ranging from 18 to 22 bp and having a G/C content of 40-60 % were chosen as 
optimal, avoiding self-complementarity within a primer and formation of primer 
dimers. To avoid dimerization, the primer sets were analyzed for hairpin, 
heterodimer, and self dimer formation via Primer Design Tools on the 
www.cybergene.se website. 
 
Figure  2.1 :  The functional domains of PHLPP gene [90]. 
The primers designed to amplify exonic regions coding for functional domains are 
listed below in table 2.2. 
Table 2.2 : Oligonucleotide primers designed for use in mutational analysis 
Exonic region  Oligunucleotide Sequence used to amplify the exonic region  
Exon2F  5´-TATGTAGATGACCAGGAA-3´ 
Exon2R  5´-GACCACGCCACTACACTT-3´ 
Exon3F  5´- TTCTGCTTCTCTCTGTTTGC-3´ 
Exon3R  5´- AGAAGCTTGAGTGGATTCCTG-3´ 
Exon5F  5´- CCCCATTTCCTCTTTAGTTG-3´ 
Exon5R  5´- CTACGTCTCATGTGCCACACC-3´ 
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Table 2.2 : (continued) Oligonucleotide primers designed for use in mutational  
         analysis 
Exonic region  Oligunucleotide Sequence used to amplify the exonic region  
Exon6F  5´- CGGTCTACAGGTTATGGAACTTG-3´ 
Exon6R  5´- CAATATAAGAACAGCCACTCA-3´ 
Exon6.1F  5´- CGGTCTTGCACTTATGGAACTTG-3´  
Exon6.1R  5`- CATTCCAAGAAAGACCCAGA-3` 
Exon6.2F   5`- CTGGGTCTTTCTTAACAATG-3` 
Exon6.2R  5`- GCTTGTTTGCCTTAAGGTTA-3` 
Exon7F  5´- TATTAGGCTTGTGCCCATTTA-3´ 
Exon7R  5´- CCATTAGAGCAACTTTGATG-3´ 
Exon14F  5´- ACGCAGTTAGAAATGGTAAGT-3´ 
Exon14R  5´- CCTCACTGATGGGGAAACTTG-3´ 
Exon15F  5´- CTCAGCACTCGAAGTGTGGTT-3´ 
Exon15R  5´- AGCAGGTATTGCAGGAACTCT-3´ 
Exon16F  5´- AGAGCAGTCAGTGCTTTGAT-3´ 
Exon16R  5´- CCTGTTAACTCACCTCAGTG-3´ 
Exon17AF  5´- TCTGTGCACCTACAGTCGAG -3´ 
Exon17AR  5´- CCTTGATGTCCATGTTCACT -3´ 
Exon17A.1F  5´- CCCTTCTTAGCCTCTGTGG-3` 
Exon17A.1R  5´- TAGGCAGAAAGGGGTTGTG-3` 
Exon17A.2F  5´- CTACACCTAACCTCCATCCC-3` 
Exon17A.2R  5´- CCTTGATCATTCATGTTCACT-3` 
Exon17BF  5´- AGTCCTGGCAACTTTCCTC-3´ 
Exon17BR  5´- CTGCTGTTTGAACCTTCTCCT-3´ 
Exon17CF  5´- AGGAGAAGGACTAACAGCAG-3´ 
Exon17CR  5´- TCATAGTGGCAAGTCGTAAT-3´ 
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2.12.3 Amplification of Functional Domains by Polymerase Chain Reaction 
(PCR) 
Polymerase chain reaction was used to amplify the target genomic DNA sequences 
on PHLPP gene which are coding for PH, LRR, PP2C-like catalytic core, and PDZ 
binding domains. For this purpose the isolated genomic DNAs of the study and 
control group were used as templates. A standard mixture of PCR (except from the 
primers) was used to amplify the related sequences of all 11 exonic regions. 
Table 2.3 : Standard PCR mix 
Ingredient Stock Concentration Volume Final Concentration 
Taq Buffer  10X 2 μL  1X 
MgCl2  25 mM 2 μL  1.875 mM 
Forward Primer  10 pmol/μL 1,5 μL  0.5 μM  
Reverse Primer  10 pmol/μL 1,5 μL  0.5 μM  
dNTP mix  2 mM 2 μL  40 μM 
Taq Polymerase  5 U/μL 0,15 μL  0.05 U/μL 
dH2O  − 19,85 μL  − 
Template DNA  50 ng/μL 2 μL  100 ng 
FINAL       32 μL  
  
The performance of the PCR reaction is affected from the purity of the template 
DNA as well as the amplicon size (length) and content (GC%). 
2.12.4 PCR Cycle Conditions 
The PCR cycle conditions were modified in order to obtain the optimum amplicon in 
expected size. General PCR cycle conditions are listed in Table 2.4 given below. 
Annealing temperature was spesific for each primer. PCR reaction were carried out 
in Techne 512 Thermo Cycler (Thermo Scientific). 
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Table 2.4 : General PCR cycle conditions 
Cycle Number  
  
Degree  Time  Phase  
1 95 °C  10 min  Initial Denaturation  
35 
94 °C  1 min  Denaturation  
Variable 1 min Annealing  
72 °C  1 min   Elongation 
1 72 °C  10 minutes  Final Extension  
1 4°C ∞ Final Hold 
2.12.5 PCR Optimization 
For amplification of the spesific product in expected size and to increase the 
reactions efficiency, PCR conditions were optimized via changing the annealing 
temperature, Mg2+ concentration in the reaction mixture and changing the template 
DNA amount used for amplification. To optimize the annealing temperature, PCR 
reactions prepared with the same reaction mix were run at different annealing 
temperatures. Since Mg2+ is the cofactor of Taq DNA polymerase, the amplification 
efficiency changes within a scale of low to high concentrations of Mg2+. Frequent 
observations about the effect of Mg2+ concentration on PCR include the decrease in 
amplicon amount with low concentration, and unspecific amplification of non-target 
regions with high concentrations. In order to obtain the appropriate amount of Mg2+ 
for a PCR reaction, PCR mixtures were prepared where only the Mg2+ concentration 
in the reaction differed. 
2.12.6 Agarose Gel Electrophoresis of PCR Products 
Due to the size of the PCR products ranging between 195 to 360 bp, 2% agarose 
gels were prepared and used in this study. For this purpose, agarose gels were 
composed of 1 g agarose, 2 µl (0.4 μg/mL) of ethidium bromide, and 50 mL of 1X 
TAE buffer, which is diluted from 10X stock TAE. 8 μL of PCR product was mixed 
with 1 μL 6X loading dye (Fermentas) and loaded into the wells. Gene ruler 1 kb 
marker (Fermentas) was used as DNA ladder. The gels were run in 1X TAE buffer, 
at 90V with power supplier, for at least 30 minutes. The gels are observed under UV 
light. 
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2.12.7 Denaturing High Performance Liquid Chromatography (DHPLC) 
Analysis 
DHPLC is one of the most sensitive and accurate methods used in identification of 
unknown mutations. It allows fast and reliable scanning of genes or gene regions. 
Due to its high sensitivity, it detects mutations that can not be find out via gel based 
or capillary electrophoresis based systems and it also shows somatic mutation sites 
which can not be detected in sequencing systems. DHPLC technique is frequently 
applied to diagnose cancer mutations due to the large length of cancer related 
genes and low frequency of their mutations. Also DHPLC system is accepted as a 
pre-sequencing technique. 
When single chain DNA carrying a mutation or a polymorphism, is hibridized with a 
wild type single chain DNA molecule, heteroduplexes will be formed. The melting 
temperature of these heteroduplexes are lower than those of homoduplexes. In the 
application of DHPLC, wild-type and mutant alleles are hybridized @ 95ºC and 
cooled to 25ºC for 45 minutes. Semi melted  or partly denatured heteroduplexes are 
disassociated before the homoduplexes, which allows their detection.  
In DHPLC system, an amphipatic ion (triethil-amonium asetate, TEAA) in mobile 
phase, and an organic solvent (Asetonitril) is used. The positively charged amonium 
ion of TEAA binds to DNA whereas its hydrophobic ethil groups are attached to the 
column material (steady phase). Hence, a bridge will be formed between column 
material and nucleic acid. The detachment of nucleic acids bound to the column is 
achieved at a spesific temperature (Tm) via increasing asetonitril concentration 
which disrupts the interaction between TEAA and the column. Nucleic acids will then 
be separated from the column as the weak ones will disassociate first, and will be 
detected via UV detection.  
24 μL of PCR product was loaded into DHPLC plate, and the specific melting 
temperatures for DHPLC analysis were determined via WAVE software.  
2.12.8 Direct Sequencing 
Samples and controls were selected for direct sequencing analysis according to the 
DHPLC results. Selected samples carrying different peak patterns than normals 
were commercially sequenced by Macrogen (South Korea).   
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2.13 Akt-1, PTEN, Caspase 3, and PHLPP Gene Expression Studies  
In gene expression studies RNA samples of 35 pediatric AML patients and CD33+ 
cells obtained from bone marrows of 5 healthy pediatric donors were used.  
2.13.1 Gene Expression of PHLPP Functional Domains   
The PHLPP exons coding for 4 major functional domains were targeted for gene 
expression studies. For this purpose, exonic sequences coding for PH-domain, LRR 
domain, PP2C-like catalytic core, and PDZ-binding core were selected and primers 
were designed to amplify those regions Figure 2.2. 
Coding region for PH-domain encompasses exon 2, 3, and 4; for LRR-domain exon 
5, 6, and 7; for PP2C-like catalytic core exon 14, 15, 16, and 17; for PDZ binding 
region exon 17. Primer sequences to amplify coding regions for 4 functional 
domains were designed using the Primer3 software. To avoid dimerization, the 
primer sets were analyzed for hairpin, heterodimer, and self dimer formation via 
Primer Design Tools on the www.cybergene.se website.   
 
Figure  2.2 : Primer design for PHLPP gene expression domains: targeting exons  
              coding for four major functional domains of PHLPP gene. 
2.13.2 Akt-1, PTEN, and Caspase 3 Gene Expression Studies 
Furthermore, primers were selected to study gene expression of Akt-1 gene 
together with its downstream target caspase-3 gene and 2 negative regulators of Akt 
pathway, the tumour supressor PTEN and PHLPP. To normalize the results of the 
gene expression studies, house-keeping genes Abelson (ABL), beta-2-microglobulin 
(B2M), and cyclophilin (CYC) were used in gene expression studies.   
Selected primers to amplify exonic regions coding for functional domains of PHLPP, 
Akt, PTEN, caspase-3, house-keeping genes; ABL, B2M, CYC- are listed below in 
Table 2.5. 
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Table 2.5 : Primers used in gene expression studies  
Primer  Oligonucleotide sequence  
PTENF  5'-CAAGCAGATGTTTGAAACTATTCCAATG-3' 
PTENR  5'-CCTTAACCTGGCAGACCACAA-3' 
CASP3F  5'-ACATCCGGTGTCATAAAATACC-3' 
CASP3R  5'-CACAATTCGACTGGATGAAC-3' 
Akt1F  5´-ATGAGGAACGTGGCTATTGTGAAG-3´ 
Akt1R  5´-GAGGCAATCAGCCACAGTCTGGATG-3´ 
PH F  5´- AGTCATGGTATGTGGGACCT-3´ 
PH R  5´- GTGAGGTGATGGCTGTAGAA -3´ 
LRR F   5´- TGATGCAGGACTTACAGACA-3´ 
LRR R  5´- ACCAGTTGAATCCTTTCACA -3´ 
PP2C1 F  5´- AGCCCTGACGGTGAATAA-3´ 
PP2C1 R  5´- CACCAGTTCCAAGTTTCCTT-3´ 
PP2C2 F  5´- TTGGCCTTGACCTCTGCTAA -3´ 
PP2C2 R  5´- CTTGCCATCTTCAATGATAA-3´ 
PDZ F  5´-GGAAGAGGAGGTGGAAGAAA-3´ 
PDZ R  5´- TCATAGTGGCGTGGCTTAAT-3´ 
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In gene expression studies, pediatric AML patient group included 35 samples and as 
controls CD33+ cells isolated from bone marrows of 5 healthy pediatric donors were 
used.  
Gene expression studies were also performed for 40 tumour tissue samples 
including 10 colon, 10 stomach, 10 pancreas, and 10 breast cancer tumour tissues.  
2.13.3 Reverse Transcriptase Reaction: First- Strand cDNA Synthesis  
After qualification and quantification of isolated RNA, reverse transcriptase reaction 
was performed using First Strand cDNA Synthesis Kit from FERMENTAS® 
including: DEPC water, dNTP mix 10mM, 5x Reaction Buffer, Oligo(dT)18 primer (0.5 
g/ l), Moloney Murine Leukemia Virus reverse transcriptase (M-MuLV RT), and 
RiboLock (Ribonuclease Inhibitor).  
First, 5µg of total RNA was mixed with 1µl of Oligo(dT)18 primer, and DEPC water 
was added till the total volume reached 11µl on ice. The contents of the reaction 
tube was mixed and micro-centrifuged on ice. The tube was incubated at 70ºC for 5 
min, chilled on ice, and micro-centrifuged. Later, 4 l of 5x reaction buffer, 1 l 
RiboLock, and 2 l of dNTP mix were added on ice. The tube was incubated at 37ºC 
for 5 min. After that, 2 l of M-MuLV RT was added, and the tube was incubated at 
37ºC for 60 min. The reaction was stopped via heating at 70ºC for 10 min. The 
newly synthesized cDNAs are immediately placed on ice and stored at -20 °C for 
later usage. 
2.13.4 Amplification of One Strand cDNA and Quantification of the Amplicon 
2.13.4.1 Standard PCR and Agarose Gel Electrophoresis  
The target sequence in one strand cDNA synthesized via reverse transcriptase 
reaction from total RNA isolate was amplified via standard PCR reaction using 
sequence specific primer pairs for ß-actin housekeeping gene under same cycling 
conditions as aforementioned for standard PCR reaction. 
The amplicon of each PCR reaction was checked via 2% agarose gel 
electrophoresis.  
2.13.4.2 Quantitative Real Time PCR (qRT-PCR)  
The mRNA expression level of target genes in peditric AML patients and in control 
group was quantified by real-time PCR analysis using Roche Light Cycler 2.0 
instrument and the SYBR® Premix Ex TaqTM kit (TaKaRa Biotechnology) as a 
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fluorescent reporter. The following PCR cycle parameters were used: 95°C for 10 
sec, 40 cycles at 95°C for 5 sec, 60°C for 34 sec.  
The optimized reaction ingredients are given in table 2.6 and the Real-Time PCR, 
cycle conditions are given in the table 2.7 below.  
Table 2.6 : Real-Time PCR mixture  
Ingredient 1X volume Final Concentration 
dH2O 2.5 μL − 
SYBR® Premix Ex Taq
TM
 5 μL 75 nM 
Forward Primer (10 μM) 0.25 μL 250 nM 
Reverse Primer (10 μM) 0.25 μL 250 nM 
cDNA template 2 μL − 
Table 2.7 : Real-Time PCR Cycling Conditions 
Cycle Number Temperature Time Phase 
1 95°C 10 min Initial Denaturation 
35 
95°C 10 sec Denaturation 
specific for each 
primer 
10 sec Annealing 
72°C 15 sec Elongation 
 
1 
95°C  
 
Melting Curve Analysis  
70°C 15 sec 
95°C  
1 40  Cooling 
Furthermore, spesificity of the amplicons were checked by melting curve analysis 
set by the melting temperatures spesific for primers. For each sample spesific 
melting curve pattern was expected to be observed. Cycle conditions for melting 
curve analysis are given in the table 2.7 above. To ensure amplicon spesificity, 
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amplification products were loaded on 2% agarose gel and the product sizes were 
compared with the expected size for each spesific product.  
2.13.5 Relative Quantification of the Samples 
The relative quantification of the samples is done by 2-ΔΔCT method. The ΔCT values 
for PHLPP, Akt 1, PTEN, and caspase 3 were calculated via subtracting the CT 
values of each sample from the previously obtained avarage CT values for control 
genes abelson, ß2-microglobulin and cyclophilin (CT Average of Control Genes - CTCase). 
These obtained ΔCT values are then placed as the power of 2 (2
ΔCT). The resulting 
values give the relative expression levels of each sample, normalized with the 
values obtained from the control samples.  
2.14 Amplification of PHLPP Transcripts 
Reverse transcriptase PCR was applied to amplify the whole mRNA transcript of 
PHLPP gene encompassing 3600 bp. Total transcript of PHLPP gene was studied 
with cDNAs obtained from 35 pediatric AML, 40 different tumour (10 breast, 10 
stomach, 10 colon, and 10 pancreas cancer tissues), and 5 healthy control samples. 
To amplify the 3600bp mRNA product  Expand Long Taq kit (Roche) was used.  
RT-PCR reaction ingredients are given in table 2.8 and long RT-PCR cycle 
conditions are given in the table 2.9 below.  
Table 2.8 : Long RT-PCR reaction ingredients 
Ingredient 1X volume Final Concentration 
dH2O 41 μL − 
Roche Expand Long Taq Buffer1 5 μL 75 nM 
 
 
dNTPs (10mM) 2.5 μL 200nM 
Forward Primer (10 μM) 0.25 μL 250 nM 
Reverse Primer (10 μM) 0.25 μL 250 nM 
cDNA template (neat cDNA) 1 μL  
 
 
Total reaction MasterMix   50 μL  
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Table 2.9 : Long RT-PCR cycle conditions 
Cycle Number Temperature Time Phase 
1 92°C 2 min Initial Denaturation 
35 
92°C 15 sec Denaturation 
specific for each primer 30 sec Annealing 
68°C 4 min Elongation 
1 68°C 7 min Final Extension 
1 4°C ∞ Final Hold 
The PCR products were loaded on to an 1% agarose gel prepared with 1 g of 
agarose, 100 ml of 1xTAE buffer, and 3.6 µl ethidium bromide (10mg/ml). 10 kb 
GeneRuler DNA ladder (Fermentas) was used to determine fragment lengths. 
2.15 Purfication of Long RT-PCR Products from Agarose Gel  
Long RT-PCR products including PHLPP transcript variants in different sizes were 
excised from agarose gel and purified by the use of High Pure PCR Product 
Purification Kit (Roche) according to the suppliers manual.  
DNA band of interest was cut from agarose gel using an ethanol-cleaned razor 
blade on a UV light box. The excised agarose gel slice was placed in a sterile 1.5 ml 
microcentrifuge tube. The gel mass was determined by first pre-weighting the tube, 
and then reweighting the tube with the excised gel slice. 300 µl of Binding Buffer 
was added for every 100 mg agarose gel slice to the microcentrifuge tube. Then, 
agarose gel slice was dissolved in order to release the DNA. The microcentrifuge 
tube was vortexed for 15-30 sec to resuspend the gel slice in the Binding Buffer. 
The suspension was incubated for 10 min at 56°C. The tube was vortexed briefly 
every 2-3 min during incubation. After the agarose gel slice was completely 
dissolved, 150 µl of isopropanol was added for every 100 mg agarose gel slice to 
the tube. The tube was vortexed. One High Pure Filter Tube was inserted into the 
Collection Tube. The entire contents of the microcentrifuge tube was transferred into 
the upper reservoir of the Filter Tube. The tube was centrifuged at 14,000 x rpm for 
1 min. The flowthrough solution was removed and the Filter Tube was put into the 
same Collection Tube. 500 µl of Wash Buffer was added to the upper reservoir. The 
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tube was centrifuged at 14,000 x rpm for 1 min. The flowthrough solution was 
removed and the Filter Tube was reconnected with the same Collection Tube. 200 
µl of Wash Buffer was added onto the tube. Next, the tube was centrifuged at 
14,000 x rpm for 1 min. The flowthrough solution was discarded. The Filter Tube 
was combined with a clean 1.5 ml microcentrifuge tube. 50 µl of Elution Buffer was 
added to the upper reservoir of the Filter Tube. The purified DNA was eluted into the 
microcentrifuge tube by a centrifugation step at 14,000 x rpm for 1 min. The purified 
products were then loaded onto the 2% Agarose gel for the quality check. Products 
in expected size and in good quality were commercially sequenced by Macrogen 
(South Korea).  
2.16 Expression Studies at Protein Level  
Isolated total proteins from pediatric AML patients, tumour samples, and healthy 
controls were analysed for PHLPP (sc-46452), total Akt 1/2/3 (sc-8312), pAkt 
(Ser473) (sc-7985-R), pAkt (Thr308) (sc-16646-R), and PTEN (sc-6817-R) 
presence. First and compatible secondary antibodies conjugated with Alkaline 
Phosphatase were purchased from supplier SantaCruz.   
2.16.1 SDS-PAGE Gel Electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) allows 
separation of proteins according to their sizes.  
%15 Separating gel was prepared with 2.5 ml of %30 acrylamide, 1.30 ml of 1,5 M 
Tris pH 8.8, 50 µl of %10 SDS, 50 µl of %10 APS, 2 µl of TEMED, and 1.10 µl of 
dH2O. Separating gel was transferred into SDS gel casette via pipetting. A thin layer 
of isoprophanol was added onto the gel in the casette. The gel was let at room 
temperature for 30 min for polymerization. Next, the isopropanol in the casette was 
discarded with a tissue paper. %5 stacking gel was prepared via mixing; 330 µl of 
%30 acrylamide, 250 µl of 0.5 M Tris pH 6.8, 20 µl of %10 SDS, 20 µl of %10 APS, 
2 µl of TEMED, and 1.4 ml of dH2O. The stacking gel was added onto the 
polymerized separating gel in the casette and left 30 min at room temperature for 
polimerization. 5 µl of 0.4 ng/µl protein samples was mixed with 2x loading buffer 
and denatured at 95°C for 5 min. 5 µl of each sample was loaded onto SDS-PAGE 
gel. As protein ladder, SeeBlue Plus2 Prestained Protein Ladder (Invitrogen) was 
used. 7µl of protein ladder was loaded onto the SDS-PAGE gel. Electrophoresis 
was accomplished in Tri-glycine running buffer at 100 V, 250mA for 90 min. The 
content of the running gel is given in the below table 2.10.    
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Table 2.10 : Tris-glycine running buffer 
Ingredient Concentration Amount used in solution 
Tris-HCl 0,125M 3g 
Glycine 0,192M 14,4g 
%10 SDS %0,1 10ml 
dH2O  1 l 
2.16.2 Western Blot Analysis 
The protein samples separated on SDS-PAGE were transferred to a PVDF 
membrane and analysed for presence of target proteins. Transfer was performed in 
a wet blotting system at 20V, 100mA for 2.5 hours (Transfer buffer: 3 g of Tris 
25mM, 14.4 g Glycine 192mM, 200 ml of %20 Methanol, 0.05 g of %0.05 SDS, and 
1l of dH2O). PVDF membrane was washed twice with TBS buffer at room 
temperature each for 10 min. [TBS buffer: 2.4 g of NaCL, 0.06 g of KCl, 0.9 g of Tris, 
and 300 ml of dH2O (pH of the buffer was set to pH 7.4)]. Next, the membrane was 
incubated at 4°C overnight with blocking buffer which included 30 ml TBS and 900 
mg of non-fat dry milk. Next day, the membrane was washed with TTBS and TBS 
washing buffers at room temperature each for 10 min (TTBS buffer: 90µl of % 0.05 
Tween20 and 180 ml TBS). Then, the membrane was first incubated with first 
antibody blocking solution at 4°C o/n. The first antibody blocking solution included 
5µl of  First antibody (200µg/ml), 300 mg of non-fat dry milk, and 10 ml of TBS 
buffer. After treating the membrane with first antibody, the membrane was washed 
again twice with TTBS buffer and once with TBS buffer at room temperature each 
for 10 min.  Secondary antibody blocking buffer was composed of  2 µl of AP 
conjugated secondary antibody (1:5000), 300 mg of non-fat dry milk (%3), and 10 ml 
of TTBS. The membrane was incubated in secondary antibody blocking buffer for 
1.5 hour at room temperature. Next, the membrane was washed twice with TTBS 
and once with TBS buffer at room temperature each treatment was for 10 min. 
Lastly, the membrane was incubated in NCBT/BCIP solution untill the protein bands 
were detectable ( 200µl NCBT/BCIP stock solution + 10ml NBT/BCIP buffer; NCBT/ 
BCIP substrate buffer: 3 g of 0.1 M Tris-HCl pH 9.5, 1.461 g of 0.1 M NaCl2, 2.541 g 
of 0.05 M MgCl2.6H2O, and 250 ml of dH2O).   
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3. RESULTS 
3.1 Standard PCR Amplification and Visualisation of PHLPP Coding Regions 
for Four Major Functional Domains  
Polymerase chain reaction was accomplished to specifically amplify the target 
genomic DNA sequences on PHLPP gene which are coding for PH, LRR, PP2C-like 
catalytic core, and PDZ binding domains. Coding region for PH-domain 
encompasses exon 2, 3, and 4; for LRR-domain exon 5, 6, and 7; for PP2C-like 
catalytic core exon 14, 15, 16, and 17; for PDZ binding region exon 17. All PCR 
products were loaded on agarose gel. PCR amplification results of the coding 
regions are shown in Figure 3.1.A-G. 
 
 
 
Figure  3.1 : Agarose  Gel  Electrophoresis of  PHLPP coding regions for four major    
functional domains: (A) Exon 17 Standard PCR amplification results of 
exon 17 coding for PP2C-like catalytic core and PDZ binding motif. (B) 
Exon 16 Standard PCR amplification results of exon 16 coding for 
PP2C-like catalytic core. (C) Exon 15 Standard PCR amplification 
results of exon 15 coding for PP2C-like catalytic core. (D) Exon 7 
Standard PCR amplification results of exon 7 coding for LRR domain. 
(E) Exon 6 Standard PCR amplification results of exon 6 coding for 
LRR domain. (F) Exon 5 Standard PCR amplification results of exon 5 
coding for LRR domain. (G) Exon 3 Standard PCR amplification results 
of exon 3 coding for PH domain.  
A 
B 
C 
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Figure  3.1 : (continued)  Agarose  Gel   Electrophoresis  of   PHLPP coding regions  
for four major functional domains: (A) Exon 17 Standard PCR 
amplification results of exon 17 coding for PP2C-like catalytic core and 
PDZ binding motif. (B) Exon 16 Standard PCR amplification results of 
exon 16 coding for PP2C-like catalytic core. (C) Exon 15 Standard 
PCR amplification results of exon 15 coding for PP2C-like catalytic 
core. (D) Exon 7 Standard PCR amplification results of exon 7 coding 
for LRR domain. (E) Exon 6 Standard PCR amplification results of 
exon 6 coding for LRR domain. (F) Exon 5 Standard PCR amplification 
results of exon 5 coding for LRR domain. (G) Exon 3 Standard PCR 
amplification results of exon 3 coding for PH domain. 
3.2 DHPLC Analysis of PHLPP Functional Domains 
Targeted PHLPP genomic sequences coding for 4 major functional domains; PH 
domain, LRR region, PP2C-like catalytic core and PDZ binding motif were analysed 
for any sequence variations by the use of DHPLC analysis.  
The melting peak patterns observed in DHPLC analysis are given in Figures 3.2 -
3.10. Melting peak patterns of pediatric AML patient samples different from those 
observed in controls were considered to represent possible sequence variations. 
Following the analysis, samples with double melting peaks were selected for further 
sequence analysis by direct sequencing.  
D 
E 
F 
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DHPLC results of exon 2 coding for PH domain are given in the Figure 3.2. Two 
different melting peak patterns observed in pediatric AML patient samples which 
were not detected in controls.  
 
 
Figure  3.2 : DHPLC results of exon 2 coding for PH domain. 
In Figure 3.3, DHPLC result of exon 3 coding for PH domain is shown. The melting 
peak pattern of pediatric AML patient samples was different from that observed in 
controls. 
 
Figure  3.3 : DHPLC results of exon 3 coding for PH domain. 
In DHPLC analysis of exon 5 coding for LRR domain, the melting peak observed in 
pediatric AML samples was varying from the melting peak pattern of controls.  
 
Figure  3.4 : DHPLC results of exon 5 coding for LRR domain. 
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DHPLC results of exon 6 coding for LRR domain are given in the Figure 3.5. Two 
different melting peak patterns observed in pediatric AML patient samples were not 
detected in controls.  
 
 
Figure  3.5 : DHPLC results of exon 6 coding for LRR domain. 
In DHPLC analysis of exon 14 coding for PP2C-like catalytic core domain, in 
pediatric AML samples, two melting peak patterns different from each other as well 
as from that observed in control samples were identified. This result is given in 
Figure 3.6.  
 
 
Figure  3.6 : DHPLC results of exon 14 coding for PP2C-like catalytic core domain. 
The results of DHPLC analysis of exon 15 coding for PP2C-like catalytic core 
domain given in Figure 3.7 indicated that the melting peak pattern observed in 
pediatric AML samples was different from that observed in controls.   
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Figure  3.7 : DHPLC results of exon 15 coding for PP2C-like catalytic core domain. 
In pediatric AML patient samples, DHPLC analysis of exon 16 coding for PP2C-like 
catalytic core domain resulted in detection of three different melting peak patterns 
which were varying from the melting peak pattern observed in controls (Figure 3.8). 
 
 
 
Figure  3.8 : DHPLC results of exon 16 coding PP2C-like catalytic core domain.  
DHPLC results of exon 17 regions coding for PP2C-like catalytic core domain are 
given in the Figure 3.9. The melting peak patterns detected in pediatric AML patient 
samples were different from each other as well as from that observed in controls. 
The results of DHPLC analysis of exon 17 coding for PDZ binding motif are given in 
Figure 3.10. Two different melting peak patterns observed in pediatric AML samples 
were varying from that observed in controls. 
 
 
 
48 
 
 
 
Figure  3.9 : DHPLC results of exon 17 coding for PP2C-like catalytic core domain. 
 
 
Figure  3.10 : DHPLC results of exon 17 coding for PDZ binding motif.  
3.3 Direct Sequencing Results of Pediatric AML Samples Selected Following 
DHPLC Analysis 
Pediatric AML samples selected according to DHPLC mutation analysis results were 
commercially sequenced. Result of sequencing studies were analysed via 
ChromasPro tool online available at http://www.technelysium.com.au/ 
ChromasPro.html (Figure 3.11). Sequence variations found in pediatric AML 
samples are listed in table 3.1 given below. 
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59 insA (aaG-gAgt)  
Figure  3.11 : Sequence analysis via ChromasPro tool. 
Table 3.1 : Sequence Variations in Coding Regions of PHLPP Gene 
 
 
3.4 Gene Expression Studies In Pediatric AML Samples 
35 pediatric AML patients and 5 healthy controls bone marrow samples were used 
for gene expression studies. CD33+ cells of the controls were isolated by MACS 
Magnetic Bead Columns as described in section 2.4 and they were pooled together 
to be used as positive controls. The gene expression studies were performed by 
qRT-PCR as described in section 2.13.    
 
PH 
LRR 
   
PP2C 
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3.4.1 Gene Expression Analysis of PHLPP Domains in pediatric AML Patients  
The expression levels of the 4 major functional domains (PH domain, LRR, PP2C-
like catalytic core, and PDZ binding motif) were studied in order to characterize 
PHLPP gene. Expression in PH domain, PP2C-like catalytic core domain and PDZ 
binding domain in AML patients and in control group were detected. Expression of 
PH domain and PP2C-like catalytic core were significantly lower in pediatric AML 
patients compared to controls. Remarkably, expression of LRR domain in pediatric 
AML patients was not detected (Figure 3.12). 
 
Figure  3.12 :  Gene   expression  analysis   of  PHLPP   domains:  (A)  PH  domain  
 Expression  levels. (B) LRR domain expression levels. (C) PP2C-like  
 catalytic  core  expression levels. (D)  PDZ  binding  motif expression     
 levels.    
3.4.2 Akt-1, Caspase 3 and PTEN Expression in pediatric AML Patients 
Akt was found to be up-regulated in pediatric AML patients (OR=4.4 95%CI=0.04-
2.9, p=0.06). Gene expression study results showed that caspase-3 expression was 
decreased 3 times (p>0.05)  in pediatric AML patients compared to controls, which 
confirmed overactivated Akt in pediatric AML patients as caspase-3 is a downstream 
target of Akt and as a pro-apoptotic factor it is expected to be expressed lower in the 
case of upregulated Akt activation. PTEN and PHLPP expressions were also found 
to be decreased in pediatric AML patients compare to CD33+ healthy bone marrow 
cells (3 times (p>0.05), 10 times (p>0.05) and respectively) (Figure 3.13).  
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Figure  3.13 : Gene expression analysis Akt, PTEN,Caspase-3. 
3.5 Amplification of PHLPP Transcripts by RT-PCR in pediatric AML patients 
As described in section 3.4.2 the gene expression studies revealed diminished level 
of expressions of PHLPP domains. And, the significant loss of LRR domain 
expression in pediatric AML patients was further studied towards defining the 
possible transcript variants. Pediatric AML patients with very low levels of LRR 
domain expression (LRR +) and patients lacking LRR domain expression (LRR -) 
were chosen to be used in Reverse Transcriptase RT-PCR analysis for possible 
transcript amplifications as described in section 2.14. This analysis would reveal all 
the possible PHLPP transcripts in pediatric AML patients. In 15 pediatric AML 
samples having low levels of LRR domain expression, a single spesific band 
representing total transcript was observed at 3600 bps as expected. However, in 20 
pediatric AML samples lacking LRR domain expression, three different transcript 
variants varying between 1800-5000 bps were detected (Figure3.14).      
 
Figure  3.14 : PHLPP RT-PCR of total transcript. 
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Each band was excised from the agarose gel. They were purified by High Pure PCR 
Product Purification Kit (Roche) according to the suppliers manual as described in 
section 2.15. Those purified bands were then sequenced. The middle band showed 
a single nucleotide change in exon 5 at position 55 in AML LRR- patients (Figure 
3.15). The upper and the lower bands could not be sequenced due to the low 
product amount.  
 
 
Figure  3.15 :  Direct sequencing  results  of  pediatric  AML  samples showing three 
     different  transcript  variants  in   RT-PCR   studies   for  total  PHLPP  
                mRNA amplification.   
3.6 RT-PCR of LRR Domain Upstream Region  
Single exons (exon 2, 3, 4, and 5) located upstream of LRR domain coding 
sequence were amplified via RT-PCR in order to understand the underlying 
mechanisms of LRR domain expression loss in pediatric AML patients. The results 
would possibly reveal the preliminary data about the possible location of 
transcriptional regulation site in this region. Results were given in the Figure 3.16.   
       A    
     B    
             C     
             D     
Figure  3.16 : RT-PCR  results  of  LRR  upstream regions: (A)  RT-PCR  results  of  
Exon2. (B) RT-PCR results of Exon3. (C) RT-PCR results of Exon4. 
(D) RT-PCR results of Exon5. 
Expression levels of exon 2 and exon 3 were lower than those of exon 4 and exon 5.  
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3.7 Gene Expression Studies of Four Major Functional PHLPP Domains in 
Different Tumour Tissues 
The expression of 4 major functional domains (PH domain, LRR, PP2C-like catalytic 
core, and PDZ binding motif) were also studied in 10 colon, 10 stomach, 10 
pancreas, and 10 breast tumour tissues. Expression levels were determined as 
described in 2.13.3.  
Expressions of LRR domain (exon 5, exon 6 and exon 7) and PP2C-like catalytic 
core (exon 15 and exon 16) were found to be diminished in colon, stomach, 
pancreas, and breast tumour tissues (Figure 3.17 and Figure 3.18). 
 
Expression levels of B2M control gene     Expression levels of LRR domain    Expression levels of PP2C-like  
                            catalytic core 
Figure 3.17 :  Comparision   of   expression  levels   of   beta-2-microglobulin  (B2M)     
              control  gene,  LRR  domain, and  PP2C-like catalytic core in different  
             tumour tissues. 
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     Expression levels of PP2C-like  catalytic core    Expression levels of PDZ  binding domain 
 
 Figure 3.18 : Expression levels of four major PHLPP functional domains in different  
             tumour tissues. 
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PH domain expression was found to be highest in breast cancer tissues followed by 
stomach and colon tumour tissues respectively. High level of PDZ binding domain 
expression was observed in pancreas tumour tissues followed by stomach, and 
colon tumour tissues respectively. In pancreas and breast tumour tissues 
expression levels of PH and PDZ domains were negatively correlated.  
3.8 RT-PCR of PHLPP Transcripts in Tumour Tissues 
In order the determine the transcript variants, the region covering exon 2 to exon 17   
was amplified via Reverse Transcriptase (RT)-PCR in tumour tissues as described 
in section 2.14. Transcript variants different from those in pediatric AML were 
detected in tumour samples (Figure 3.19).  
 
 
Figure 3.19 : PHLPP transcript variants in tumour tissues. 
3.9 Western Blot Studies 
The expression of total Akt 1/2/3, phospo-Akt (Ser 473) spesific, phospho-Akt (Thr 
308) spesific, and two negative regulators of Akt signalling pathway; tumour 
suppressors PTEN and PHLPP, were studied at protein level in pediatric AML 
patients samples by the use of Western Blot Analysis as described in section 2.15.2. 
Pediatric AML samples were analyzed by Western blotting employing antibodies for 
Akt, pAkt Ser473, pAkt Thr308. Akt and phosphorylated Akt at two specific sites 
were detected in Western blot analysis as shown in Figure 3.20.A and 3.20.C-D. A 
well known tumour suppressor PTEN was also detected at protein level in pediatric 
AML samples (Figure 3.20.B). However, another tumour suppressor, PHLPP protein 
expression was found to be lost in pediatric AML patients as shown in Figure 3.20.E.  
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Figure 3.20 : Western Blot Analysis of pediatric AML patients. (A) Total Akt1/2/3 
was detected in pediatric AML patient samples as well as commercial positive 
control. (B) PTEN expression was observed in pediatric AML patients and in 
commercial positive control. (C) Phosphorylated Akt specific at Ser473 was 
observed both in pediatric AML samples and commercial positive control. (D) 
Phosphorylated Akt specific at Thr308 was observed both in pediatric AML samples 
and commercial positive control. (E) PHLPP expression was not detected in 
pediatric AML samples but in commercial positive control.       
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4. DISCUSSION AND CONCLUSION 
PI3K/Akt signalling pathway has been reported to be frequently activated in AML. 
Studies showed that upregulated PI3K/Akt signalling strongly contributes to 
proliferation, survival and drug resistance of AML blasts. Moreover, both the 
disease-free survival and overall survival has been reported to be significantly shorter 
in AML cases with upregulated PI3K/Akt pathway [32-35]. 
Since the molecular analysis of PHLPP gene has not been elucidated, in this study it 
is aimed to identify sequential variations in the PHLPP coding regions for four major 
functional domains together with their expression levels. 
To accomplish the mutational analysis, Denaturing High Performance Liquid 
Chromatography (DHPLC) method was applied since it is suggested to be one of the 
most sensitive and accurate methods used in identification of unknown mutations. It 
allows to detect mutations that can not be identified via gel or capillary 
electrophoresis based systems and also it shows somatic mutation sites which can not 
be detected in sequencing systems. DHPLC technique is frequently applied to 
diagnose cancer mutations due to the large length of cancer related genes and low 
frequency of their mutations. Also DHPLC system is accepted as a pre-sequencing 
technique. Sequence variations found in PHLPP coding regions for four major 
functional domains included single base changes which might result in amino acid 
substitution and related charge change at protein level. Those changes might also 
affect the protein structure and function. Due to the sequence variations, the function 
of PHLPP, a novel tumour suppressor on Akt signalling pathway, might be impaired. 
This might further lead to upregulation of Akt pathway in pediatric AML. Nearly 
half of pediatric AML patients were carrying 599insA (S200R) in coding region for 
LRR domain. It is known that LRR domain is involved at protein-protein interaction, 
so the changes at amino acid charges might lead structural and functional changes at 
PHLPP protein phosphatase. There are also sequence variants found in pediatric 
AML patients but not in healthy controls in coding regions for PH domain exon2; 
59insA (5.2%), 60T>G (2.8%), 77C>A (2.8%), 109A>T (2.8%), exon3; 289C>A 
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(7.8%), 352C>A (7.8%), 343insA (2.8%), and PP2C-like catalytic core exon14; 
1980T>C (5.2%), 1992T>C (5.2%), exon17; 3280C>A (13.1%), 3302insA (13,1%), 
3303T>C (13.1), 3407insA (5.2%) and 3611insC (7.8%) , which might also result in 
charge and polarity change at protein level. It is known that PH domain binds to 
phosphorylated Ser/Thr residues. A structural change in this domain due to 
sequential variations might disrupt the interaction of PHLPP directly with 
phosphorylated Akt at Ser473 residue. Variations at PP2C-like catalytic core of 
PHLPP and regarding charge and polarity changes at protein level might interfere 
with PHLPP function as a protein phosphatase. 
The expression studies were performed in 35 pediatric AML patients and in healthy 
controls; peripheral blood samples and CD33+ bone marrow cells by qRT-PCR. The 
results revealed that Akt was up-regulated in AML patients that were examined 
(OR=4.4 95%CI=0.04-2.9, p=0.06). PI3K/Akt signalling pathway has been reported 
to be frequently activated in AML [32-35]. However, there is no previous data 
reporting Akt expression levels in pediatric AML patients. Moreover, constitutive 
activation of PI3K/Akt pathway has been implicated in the both the pathogenesis and 
the progression of a wide variety of neoplasias. Overexpression of Akt/PKB was
 
demonstrated to in colorectal carcinogenesis [25], in gastric carcinomas [26], 
pancreatic cancers [27], and also in breast tumours [28]. PTEN, PHLPP and caspase-
3 were found to be decreased in pediatric AML patients compared to CD33+ healthy 
bone marrow cells (3 times (p>0.05), 10 times (p>0.05) and 3 times (p>0.05) 
respectively). In previous studies, PTEN mRNA expression was found to be lower in 
AML patients compared to normal controls (60.0 % vs 90.%, p<0.05) [102]. In this 
study the difference in PTEN expression levels between pediatric AML patients and 
controls was found higher compared to this reference, where PTEN expression was 
studied in adult AML patient group. The expression of caspase 3, an apoptosis 
related gene; was found  to be lower in pediatric AML patients than in control group. 
The decrease in expression levels were as expected because when activated Akt 
inhibits downstream pro-apoptotic targets. Both cleaved and uncleaved caspase 3 
levels reported to be higher in AML blasts and adult AML patients. Moreover, high 
levels of uncleaved caspase 3 was associated with decreased survival. Conversely, 
high levels of cleaved caspase 3 denoted improved survival and correlated with the 
inactivation of the DNA-repair enzyme poly (ADP-ribose) polymerase [60].  
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Gene expression studies revealed that the expression of PH domain and PP2C-like 
catalytic core were diminished whereas LRR domain expression was lost in pediatric 
AML patients. LRR domain is known to be involved at protein-protein interaction. It 
has also been reported that in the LRR cassette domain of LRRC4, a putative tumour 
suppressor gene, the third LRR motif of the core LRR plays a crucial role as a 
“proliferation-inhibition switch”. Moreover, it is proposed that LRRC4 requires a 
functional LRR cassette domain to inhibit proliferation of glioma cells in vitro by 
modulating the extracellular signal-regulated kinase/protein kinase B/nuclear factor-
κB pathway [98]. LRR domain might also be curicial for appropriate function of 
PHLPP as a Akt pathway off-switch. The insertion found in exon 5 in the LRR 
coding region in nearly half of the patients and the gene expression studies indicating 
LRR domain loss in patients might lead one to speculate that impaired LRR domain 
function might affect PHLPP function as a protein phosphatase. Recently, Ouillette 
et al. also studied PHLPP expression in Chronic Lymphocytic Leukemia (CLL) 
patients with deletion 13q14 and found the loss of PHLPP expression in those 
patients [101]. Interestingly, expression level of PDZ binding motif was found to be 
higher in patient group than in controls. Different level of expressions determined in 
functional domains of PHLPP might be due to the epigenetic regulations. Further 
analysis performed by RT-PCR studies for amplification of PHLPP mRNA from 
exon 2 to exon 17 in pediatric AML patients lacking LRR domain showed three 
different PHLPP transcript variants at different sizes. However, pediatric AML 
samples having very low level of LRR domain expression revealed only one spesific 
mRNA transcript at expected size. Direct sequencing results showed a single 
nucleotide change in exon 5 at position 55 in pediatric AML samples lacking LRR 
expression. Upstream LRR domain (exon 2, exon 3, exon 4 and exon 5) was 
investigated in order to identify the susceptible regions carrying possible regulatory 
sites affecting LRR domain expression in pediatric AML patients. It was detected 
that expression levels of exon 2 and exon 3 were lower than those of exon 4 and exon 
5. This result might indicate that upstream exon 4 is the possible location of 
transcriptional regulatory site. 
Expression studies of four major functional PHLPP domains in tumour tissues 
(colon, stomach, pancreas and breast) showed diminished level of LRR domain 
expression and loss of PP2C like catalytic core expression. Liu et al. has recently 
 
60 
found loss of PHLPP expression in colon cancer [100]. This result is in concordance 
with our data. The loss of PHLPP confirms it being a tumour suppressor gene in 
tumourigenesis and leukemogenesis. Furthermore, PHLPP mRNA transcript variants 
different from those in pediatric AML patients were detected in tumour samples. The 
role of epigenetic regulation in cancer progression might explain the PHLPP 
transcript variants in different sizes observed in pediatric AML and tumours.  
Expression studies at protein level by Western Blot Analysis confirmed the results of 
the gene expression studies. Total Akt 1/2/3 was present in pediatric AML patients. 
Also pAkt (Ser 473) and pAkt (Thr 308) were detected in pediatric AML patient 
samples. One of the two tumour suppressors acting negatively on Akt pathway, 
PTEN, was also found to be expressed at protein level in AML patients, whereas 
PHLPP expression could not be detected at Western Blot Analysis. Commercial 
antibody used in PHLPP detection was raised against a peptide mapping at the N-
terminus of PHLPP. In this study, sequence variations in coding regions for N-
terminal PH domain of PHLPP were found, which might further lead to a structural 
change at protein level hindering proper detection of PHLPP with the antibody used. 
Antibodies for western blot analysis of PHLPP might be raised against different 
PHLPP regions to visualise the protein or possible truncated forms of  the protein.  
To sum up, this is the first study evaluating sequence variations together with the 
expression of PHLPP gene in pediatric AML and solid tumours. Considering the 
results of this study, it can be proposed that PHLPP gene might act as a tumor 
suppressor in AML leukomogenesis and this can provide an important guidepost for 
the development of diagnostic tools for acute leukemia. Further functional studies are 
needed to determine the impacts of sequential variations to PHLPP protein structure 
and function. Also, to decide if the sequential variations are mutations or 
polymorphisms populations studies in larger number can be accomplished. The 
599insA (S200R) in coding region for LRR domain observed in %47 of pediatric 
AML patients should be further examined in order to determine the role of LRR 
domain in PHLPP and also its effect in cancer progression.The role of epigenetic 
regulation in cancer might explain the presence of PHLPP transcript variants in 
pediatric AML samples and different tumour tissues. Therefore, the possible 
underlying mechanisms need further be studied. 
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APPENDIX A 
LABORATORY EQUIPMENT 
Balances  Schimadzu 
 Precisa  
Centrifuges      Eppendorf 
Allegra 25R Centrifuge Beckman 
Coulter 
       Sigma 
Minicentrifuge     Beckman coulter  
Electrophoresis Equipments   Stratagene 
Gel Documentation System   BIO-RAD 
Mini-Vertical Gel System    BioWorld 
Orbital Shaker     Forma 
Thermomixer                 Eppendorf 
Microplate Reader      Biorad 
Spectrophotometer  NanoDropTM 1000 
Spectrophotometer, Thermo 
Scientific 
MiniMACS Column                            Miltenyi Biotec 
MACS Separator   Miltenyi Biotec 
pH meter      Mettler Toledo MP220 
Real time PCR     Roche Lightcycler 1.2 
Thermo cycler     Techne 512 Thermo Cycler,  
Thermo Scientific 
dHPLC      Wave System 
Flow Cytometer  Becton Dickinson BD 
FACSCalibur Flow Cytometer 
Vortex       Kermanlar 
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Pipettes      Gilson Pipetman  1000 μl 
            Thermo Finnpipette 10 µL, 200 μl  
Laminar Air Flow Cabin               Thermo Scientific 
Fridge and Freezers (+4°C, -20°C, -80°C)  Heraeus Sepatech, Bosch, 
Sanyo, Arcelik 
 
Water Distillation System     Millipore 
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APPENDIX B 
CHEMICALS 
Acrylamide Merck 
Agarose      Sigma 
Antibodies for Western Blot             Santa Cruz 
Studies:   
Akt1/2/3 (H-136) sc-8312                  
p-Akt1/2/3 (Ser 473)-R sc-7985-R    
p-Akt1/2/3 (Thr 308)-R sc-16646-R  
 PTEN (C-20)-R sc:6817-R 
SCOP (N-12) sc-46452 
Donkey anti-goat IgG AP sc-2022 
Donkey anti-rabbit IgG AP sc-2315 
Positive controls for Western         Santa Cruz 
Blot Studies: 
Y79 nuclear extract sc-2126 
KNRK Whole Cell Lysate sc-2214 
A-431 + EGF Whole Cell Lysate sc-2202  
B-Mercaptoethanol   Sigma 
Bromophenol Blue   Sigma 
Buffer D   Wave System  
dNTP   Fermentas 
DTT (Dithiothreitol)   Fermentas 
EDTA   Sigma 
Ethanol   Merck 
  Riedel-de Haën 
Ethidium Bromide   Sigma 
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Ficoll  Sigma Histopaque 
Glacial Acetic Acid  Merck  
Glycerol  Sigma  
Glycine  Merck 
Isopropanol  Fluka 
KCl  Carlo Erba    
MgCl2 Fermentas 
NaCl Carlo Erba 
NaH2PO4 Riedel-de Haën 
Na2HPO4.7H2O  Riedel-de Haën 
NaOH Riedel-de Haën 
PVDF membrane Roche 
Primers Integrated DNA Technologies,Inc. XX IDT  
Random Primer Fermentas 
Sodium dodecyl sulfate (SDS)  Merck 
Syringe Wash Solution Wave System 
TEAA Buffer A Wave System 
TEAA Buffer B Wave System 
TEMED Merck  
Tris Base Merck 
 Sigma 
2-mercapto-ethanol Merck 
10X PCR Buffer Fermentas 
5X Reverse Transcriptase Buffer Fermentas 
6X Sample Loading Dye  Fermentas 
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ENZYMES 
Expand Long Taq Polymerase Roche 
Reverse Transcriptase     Fermentas 
SYBR Premix Ex Taq    Takara 
Taq DNA Polymerase                        Fermentas 
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MARKERS 
Gene RulerTM 1 kb DNA Ladder    Fermentas 
 
 
 
 
PageRuler™ Prestained Protein Ladder  Fermentas 
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pUC Mix Marker, 8  Fermentas 
 
SeeBlue Plus2 Prestained Protein Ladder   Invitrogen 
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APPENDIX C 
SOLUTIONS and BUFFERS 
Ethidium Bromide 
Ethidium bromide dilution of a final concentration 10mg/ml was prepared with dH2O 
and EtBr stock.   
Solution D 
100 µl of ß-Mercaptoethanol was added to 10 ml of Buffer RLT (erythrocyte lysis 
buffer).  
SDS Sample Buffer (10 ml, 2X) 
                                                                             Final Concentration 
Tris-HCl pH 6.8, 0.5 M  2.5 ml                        0.12 M 
SDS (10%)                                       4 ml                          %4 
Glycerol  (100%)     2 ml       %20 
Bromophenol blue     5 mg      % 0.05 
DTT (dithiothreitol) 231 mg  0.15 
dH2O added to 100 ml.    
TAE (Tris-Acetat-EDTA) Buffer (500 ml, 50X) 
Tris base    121 g  
Glacial Acetic Acid   28.5 ml 
EDTA     50 ml (0.5 M, pH 8.0) 
dH2O was added to 500 ml and the pH was adjusted to 8.0  
Tris-glycine Running Buffer 
                                                                             Final Concentration 
Tris base      3 g                            0.125 M 
Glycine    14.4 g              0.192 M 
SDS (10%)                                     10 ml                        % 0.1 
dH2O added to 1 l.    
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Transfer Buffer  
                                                                                      Final Concentration 
Tris base      3 g                               125 mM 
Glycine    14.4 g                  192 mM 
Methanol     200 ml                           %20 
SDS                                               0.05 g                            % 0.05 
dH2O added to 1 l.    
TBS  
NaCl     2.4 g 
KCl     0.06 g  
Tris      0.9 g 
dH2O was added to 300 ml and the pH was adjusted to 7.4.  
TTBS 
Tween20                                        90 µl  
TBS               180 ml  
BCIP/ NBT Substrate Buffer 
Tris-HCl pH 9.5, 0.1 M                     3 g  
NaCl2                                              1.461 g 
MgCl2.6H2O                                     2.541 g 
dH2O was added to 250 ml.  
10X Phosphate Buffered Saline (PBS) 
NaCl      90 g 
Na2HPO4.7H2O    26.8 g 
NaH2PO4     3.2 g 
dH2O was added to 1 l and the pH was adjusted to 7.2 after every 1/10 dilution. 
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APPENDIX D 
USED KITS 
DNA, RNA, Protein Isolation Qiagen, AllPrep Mini Kit  
RNA Isolation Qiagen, RNA Mini Blood Kit   
cDNA synthesis kit Fermantas, RevertAidTM First Strand cDNA 
Synthesis Kit 
Real-Time PCR Takara, SYBR Premix Ex Taq 
High Pure PCR Product 
Purification Kit Roche 
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